Disorders of gustation

Douglas J Lanska MD MS MSPH

General Neurology

Updated 05.28.2024
Released 10.17.2022
Expires For CME 05.28.2027

Disorders of gustation

Author: Douglas J Lanska MD MS MSPH

See Contributor Disclosures

Disorders of gustation

In This Article

Quick Link

Introduction

Historical note and terminology

Galen (129-201 CE) correctly described the different functions of the three principal nerves supplying the tongue (lingual, glossopharyngeal, and hypoglossal nerves) and demonstrated their origin at the base of the brain (217).

Printed medical illustrations began in 1490 and, by the beginning of the 16th century, included representations of afferent connections from the special sensory organs to the brain (117). These were typically part of highly schematic diagrams of brain function representing the medieval cell doctrine, in which usually three “cells” or ventricles were assigned functions of sensory integration and imagination, cognition, and memory (118). Indeed, many early-16th-century woodcuts of the medieval cell doctrine show presumptive connections between the organs subserving the special senses, either with the most anterior cell or ventricle of the brain or with a specific portion of it--the sensus communis (ie, sensory commune, or common sense, a structure Aristotle had postulated is responsible for monitoring and integrating the panoply of sensations from which unified conscious experience arises) (117; 118; 119). A representation of the tongue and presumptive pathways to the brain are incorporated into many of these woodcuts (119; 119). These stereotyped 16th-century schematic images typically linked the tongue to an anterior cell or a portion of it. Such images linked the gustation via the tongue to "cells" of "ventricles" before the advent of more realistic images and schematics began to show the neural gustatory pathways beginning in the mid-sixteenth century.

Observational anatomy was largely lost from the time of Galen in the second century, and it became regimented and dogmatized with the scholasticism of the Middle Ages until a few anatomists began to seriously challenge Galen beginning in the 16th century. Most notably, Flemish anatomist Andreas Vesalius (1514-1564) provided much greater realism with the publication of his de Humani corporis fabrica (1543).

Woodcut of Flemish anatomist Andreas Vesalius (1514-1564) performing a public dissection on a woman

(Source: Vesalius' de Humani corporis fabrica [1543]. Courtesy of the U.S. National Library of Medicine, Bethesda, Maryland. Woodcut print edited by Dr. Douglas J Lanska.)
Woodcut of Flemish anatomist Andreas Vesalius (1514-1564) performing a public dissection on a woman (close-up detail)

(Source: Vesalius' de Humani corporis fabrica [1543]. Courtesy of the U.S. National Library of Medicine, Bethesda, Maryland. Woodcut print edited by Dr. Douglas J Lanska.)

Vesalius depicted dissection of the face, isolating the tongue, as part of one of his elaborate depictions of the famous “musclemen.”

Vesalian "muscleman" woodcut, including dissection of the mouth and mandible

(Source: Vesalius' de Humani corporis fabrica [1543]. Courtesy of the U.S. National Library of Medicine, Bethesda, Maryland. Woodcut print edited by Dr. Douglas J Lanska.)
Vesalian "muscleman" woodcut, including dissection of the mouth and mandible (close-up detail)

The mandible has been split in the midline and separated. (Source: Vesalius' de Humani corporis fabrica [1543]. Courtesy of the U.S. National Library of Medicine, Bethesda, Maryland. Woodcut print edited by Dr. Douglas...

Vesalius also separately made a schematic of the cranial nerves, including innervation of the tongue, but the pathway for taste sensation had not been determined by this point.

Vesalius' woodcut schematic of the cranial nerves

(Source: Vesalius' de Humani corporis fabrica [1543]. Courtesy of the U.S. National Library of Medicine, Bethesda, Maryland. Woodcut print edited by Dr. Douglas J Lanska.)
Vesalius' woodcut schematic of the cranial nerves (close-up detail)

(Source: Vesalius' de Humani corporis fabrica [1543]. Courtesy of the U.S. National Library of Medicine, Bethesda, Maryland. Woodcut print edited by Dr. Douglas J Lanska.)

Even after Vesalius championed a return to observational anatomy, the medieval cell doctrine and its associated representation of the olfactory pathways persisted well into the 19th century, even if it was gradually moved to the fringes of medical thought (119).

By the 18th century, anatomists were working to realistically represent anatomical structures, as epitomized by the copperplate engravings of Dutch Golden Age physician, anatomist, poet, and playwright Govert Bidloo or Govard Bidloo (1649-1713).

Dutch Golden Age physician, anatomist, poet, and playwright Govert Bidloo or Govard Bidloo (1649-1713)

(Source: Bidloo's Ontleding des menschelyken lichaams [1690]. Courtesy of the U.S. National Library of Medicine, Bethesda, Maryland. Woodcut print edited by Dr. Douglas J Lanska.)
Bidloo's copper plate of the beginning dissection of the face (1690)

Copper plate shows the tongue, palate, uvula, and epiglottis (behind the posterior aspect of the tongue). (Source: Bidloo's Ontleding des menschelyken lichaams [1690]. Courtesy of the U.S. National Library of Medicine,...

This continued into the 19th century, with amazingly realistic and detailed colored lithographs, including the outstanding examples of Irish-born English anatomist Richard Quain (1800-1887) and German anatomist Christian Wilhelm Braune (1831-1892) in his topographical anatomy atlas (1867-1872).

Irish-born English anatomist and surgeon Richard Quain (1800-1887)

Lithograph by T Bridgford. (Courtesy of the Wellcome Collection. Creative Commons Attribution 4.0 International [CC BY 4.0] License, https://creativecommons.org/licenses/by/4.0. Image edited by Dr. Douglas J Lanska.)
Dissection of the head and neck showing the lingual nerve, detail (cut away)

The lingual nerve passes through the cheek and underneath the anterior border of the mandible. The lingual nerve has been colored blue here for ease of visualization. (Source: Quain R. The anatomy of the arteries of the human b...
Dissection of the head and neck showing the lingual nerve (cut away)

The lingual nerve passes through the cheek and underneath the anterior border of the mandible. (Source: Quain R. The anatomy of the arteries of the human body, with its applications to pathology and operative surgery: in lithog...
Sagittal section of the head, neck, and upper thorax

Colored lithograph from German anatomist Christian Wilhelm Braune (1831-1892). (Source: Braune's Topographisch-anatomischer Atlas : nach Durchschnitten an gefrornen Cadavern [1867-1872]. Courtesy of the U.S. National Library of...
Sagittal section of the head (detail)

Colored lithograph from German anatomist Christian Wilhelm Braune (1831-1892). (Source: Braune's Topographisch-anatomischer Atlas : nach Durchschnitten an gefrornen Cadavern [1867-1872]. Courtesy of the U.S. National Library of...

The structure of the tongue surface was first described in 1609 by Italian anatomist Giulio Cesare Casseri (1552-1616), and then in 1665 by Italian physician-anatomist Lorenzo Bellini (1643-1704), who published the observations made by Italian biologist, physician, and pioneering microscopist Marcello Malpighi (1628-1694) the previous year (100; 217). After the discovery of taste buds in fishes by German zoologist and comparative anatomist Franz von Leydig (1821-1908) in 1851, German anatomist and zoologist Franz Eilhard Schulze (1840-1921) suggested in 1863 that they were chemosensory structures. Nineteenth-century studies focused on cytologic features and nerve supply. By the late 19th century, physicians were readily examining tongues for clinical clues to their patients' illnesses, and this became the subject of numerous caricatures.

Portrait of Italian anatomist Giulio Cesare Casseri (1552-1616)

Italian anatomist Giulio Cesare Casseri, also known as Julius Casserius, anatomist in Padua, possibly by Gijsbert van Veen, 1591. (Courtesy of the Rijkmuseum, Amsterdam, The Netherlands. Public domain.)
Line engraving of Italian anatomist Giulio Casserio (1552-1616)

Italian anatomist Giulio Casserio (Julius Casserius). (Courtesy of the Wellcome Library, London, UK. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0.)
Italian physician-anatomist Lorenzo Bellini (1643-1704)

(Source: Wikimedia Commons. Public domain.)
Italian biologist, physician, and pioneering microscopist Marcello Malpighi (1628-1694)

Painting by Carlo Cignani (1628-1719). (Source: Wikimedia Commons. Public domain.)
German zoologist and comparative anatomist Franz von Leydig (1821-1908)

(Courtesy of the Bibliothèque interuniversitaire de Santé, Paris, France. Open License, version 1.0, fr.wikisource.org/wiki/Licence_Ouverte,_version_1.0.)
German anatomist and zoologist Franz Eilhard Schulze (1840-1921) in 1884

Photograph by Leopold Bude (1840-1907). (Source: University Archive of the Karl-Franzens University of Graz, Graz, Austria. Public domain.)
"The end of the feast” (watercolor by Cynicus)

A patient poking out his tongue and having his pulse taken by a physician. Watercolor by Cynicus. Martin Anderson (1854-1932), better known by his pseudonym Cynicus, was a Scottish artist, political cartoonist, postcard illustr...
A physician examines a patient's tongue. Lithograph by Charles Vernier, 1853

"Le docteur. _ Ah! ... si vous avez mangé du raisin tout s'explique: vous avez alors la maladie des pommes de terre dont le remède est encore inconnu ... tranquillisez-vous!" [“The doctor. _ Ah! ... if you have eaten grapes, ev...
Sick man projects his tongue while a doctor takes his pulse. Colored lithograph

The patient holds green spectacles in his left hand. The woman holds a cup with a spoon. Lettering: Der patient (Das Vertrauen). A patient (Confidence). (Source: F. Silber, Berlin, Germany. Courtesy of the Wellcome Library, Lon...

Clinical manifestations

Presentation and course

	• Patients with gustatory symptoms generally report diminution or absence of gustatory sensation (hypogeusia or ageusia, respectively) and forms of distorted gustation (parageusia).
	• Except in unusual circumstances, hypergeusia is a subjective sensation of hyperacuteness of gustation.
	• There is no evidence that pregnant women or migraineurs experience an objective increase in gustatory sensitivity.
	• When patients report alterations in the quality of gustation in response to a tastant (ie, parageusias), the perceptions are almost universally unpleasant, a condition referred to as aliageusia (the perception of unpleasant taste from something that usually tastes pleasant).
	• Aliageusias may involve the perception of fecal or rotten tastes (cacogeusia) or chemical or burned tastes (torqugeusia).
	• Complaints of impaired “taste” are often symptoms of olfactory dysfunction because much of the flavor of a meal derives from olfactory stimulation. Indeed, the complex sensory experience of “flavor” during the consumption of foods and drinks cannot be constructed simply from combinations of the basic taste qualities (sweet, salty, sour, bitter, and umami or savory).
	• Chemosensory deficit may be the first symptom--a "sentinel symptom"--in patients with COVID-19, but there is wide variation in the proportion of cases in which this is reported to occur.
	• Presbygeusia (literally “elderly gustation” or “old-age gustation”) is the gradual loss of gustatory abilities that occurs in most people as they grow older.
	• Clinically significant gustatory loss is common in the elderly but frequently unrecognized, in part, because deficits typically accumulate gradually over decades--indeed, self-reported gustatory impairment significantly underestimates prevalence rates obtained by gustatory testing.

Patients use various expressions to describe disorders of taste or gustation (Table 1) (116).

Table 1. Terminology for Gustatory Function

Category	Term
Disturbance of perception (any)	Dysgeusia
Alteration of quantity	Absent	Ageusia
	Decreased	Hypogeusia
	Normal	Normogeusia
	Increased	Hypergeusia
Alteration of quality	Distorted (any) [general term]	Parageusia
	Specific distortions
	1	Any unpleasant distortion of taste	Aliageusia
	2	"Abhorrent, obnoxious," typically fecal or putrid	Cacogeusia
	3	"Twisted": chemical, metallic, bitter, salty, or burned	Torqugeusia
	4	Inappropriate chemosensory quality of consistent nature¹	Heterogeusia
Hallucination²	Phantageusia
¹ "Unusual and unexpected but not necessarily foul or obnoxious" (81). ² No evident stimulus (odorant) in the external milieu.

Patients with gustatory symptoms generally report diminution or absence of gustatory sensation (hypogeusia or ageusia, respectively) and forms of distorted olfaction (parageusia). Except in unusual circumstances, hypergeusia is a subjective sensation of hyperacuteness of gustation. There is, for example, no evidence that pregnant women or migraineurs experience an objective increase in gustatory sensitivity.

When patients report alterations in the quality of gustation in response to a tastant (ie, parageusias), the perceptions are almost universally unpleasant, a condition referred to as aliageusia (the perception of unpleasant taste from something that usually tastes pleasant). Aliageusias, for example, may involve the perception of fecal or rotten tastes (cacogeusia) or of chemical or burned tastes (torqugeusia).

The terminology for alterations in the quality of a gustatory perception (eg, cacogeusia, torqugeusia) can also be employed with hallucinated odors (phantageusias); thus, one can speak of a "cacogeusic phantageusia" for the hallucination of a fecal taste or a "torqugeusic phantageusia" for the hallucination of a burned taste (82).

In addition, complaints of impaired “taste” are often symptoms of olfactory dysfunction because much of the flavor of a meal derives from olfactory stimulation. Indeed, the complex sensory experience of “flavor” during the consumption of foods and drinks cannot be constructed simply from combinations of the basic taste qualities (sweet, salty, sour, bitter, and umami or savory).

Dysgeusia in COVID-19. Disorders of the smell and taste are more common among individuals with COVID-19 than among individuals with influenza (28). Chemosensory clinical symptoms are present in at least half of patients with COVID-19 (05; 20; 145; 146; 168; 59). In one study of 922 participants, 20% reported ageusia, 5% reported hypogeusia, and 32% reported hypogeusia and dysgeusia (05).

The risk of COVID-19-associated smell or taste disturbance has progressively fallen with successive waves of infection with the Alpha, Delta, Omicron K, Omicron L, Omicron C, and Omicron B variants, based on their peak intervals (169); consequently, since the Omicron waves, smell and taste disturbances have been of less predictive value in the diagnosis of COVID-19 infection (169).

A chemosensory deficit may be the first symptom--a "sentinel symptom"--in patients with COVID-19, but there is wide variation in the proportion of cases in which this is reported to occur (39; 40; 41; 66; 99; 101; 160; 177; 38; 163). A meta-analysis of eight studies involving 11,054 patients with COVID-19 reported that olfactory and gustatory symptoms appear prior to general COVID-19 symptoms in 65% and 54% of the patients, respectively, based on European, United States, and Iranian data (180). However, a systematic review of 17 studies found the onset of dysosmia and dysgeusia occurred 4 to 5 days after other symptoms of the infection and that these chemosensory symptoms typically improved after 1 week, with more significant improvements in the first 2 weeks (182).

New-onset chemosensory dysfunction is also common in patients with symptomatic COVID-19 after complete vaccination. In one study of 153 such patients, approximately half reported associated rhinorrhea, which is a much higher proportion than in unvaccinated cases (209).

Available reports present conflicting data on whether COVID-19 severity is associated with either the degree of gustatory dysfunction or the prognosis for recovery of gustation, but multiple reports suggested that chemosensory symptoms were most common among those with milder presentations of COVID-19 (25; 43; 167; 184).

Psychophysical testing showed significantly reduced intensity perception and identification ability for both taste and smell functions in patients with COVID-19 (31), although some studies using quantitative testing found olfactory disturbances in nearly all subjects during the acute infection phase, whereas taste or chemesthetic deficits were low (65; 146). Curiously, psychophysical data produced substantially lower estimates of dysgeusia after COVID-19, perhaps because of misinterpretation of impaired retronasal olfaction as gustatory dysfunction (86). Smell and taste loss in COVID-19 are closely associated, although a minority of individuals can experience one or the other (32; 59). Most patients with taste dysfunction after COVID-19 did not have true taste dysfunction, but rather perceived altered flavor sensations associated with olfactory dysfunction (146). The taste of salt may be less severely affected than other taste qualities (32), whereas complete loss of bitter taste was the most prevalent specific ageusia (173).

Chemosensory impairment may be persistent (17; 20; 145; 146; 168), even 1, 2, or 3 years after mild COVID-19 (17; 20; 146; 191), although chemosensory recovery from the Omicron BA.1 subvariant was more favorable than that after the first wave of the pandemic (19). In a prospective observational study, measuring the prevalence of altered sense of smell or taste at follow-up and their variation from baseline, on 403 consecutively assessed adult patients who tested positive for SARS-CoV-2 RNA by polymerase chain reaction during March 2020, 66% reported an altered sense of smell or taste at baseline, whereas 14%, 7%, and 5% reported such alterations at 6 to 24 months, 2 years, and 3 years, respectively (20). Late improvement was possible: of the patients who still experienced smell or taste dysfunction 2 years after COVID-19, 28% and 38% recovered completely and partially, respectively, at the 3-year follow-up (21). Olfactory dysfunction is most likely to persist after 1 year, whereas objectively measured taste dysfunction has typically recovered by that time (191).

Gustatory hallucinations (phantageusias)

Gustatory hallucinations (phantageusias) can occur through irritative (eg, epilepsy, migraine) or "release" (eg, ageusia or hypogeusia) mechanisms (42).

Phantageusia and phantosmia are associated with decreased brain GABA levels (126). In a study of olfactory and gustatory hallucinations in 28 normal volunteers and 19 patients with persistent phantageusia or phantosmia, GABA levels in several CNS regions (ie, the cingulate, right and left insula, and left amygdala) were lower in patients before treatment than in normal volunteers and were the only biochemical changes found (126). After treatment that inhibited sensory distortions, CNS GABA levels increased to levels at or near normal, consistent with functional remission of these symptoms.

Epileptic olfactory and gustatory hallucinations. Olfactory hallucinations often occur with a lesion in the inferior and medial parts of the temporal lobe, whereas gustatory hallucinations can occur in temporal lobe disease with lesions in the insula and parietal operculum (109). Of course, epileptic discharges can also spread to these areas from areas that are proximate or intimately connected with the temporal lobe, operculum, and insula (96). For example, a 4-year-old boy had ictal fear as his primary epileptic manifestation, associated with complex visual and gustatory hallucinations, oral automatisms, and pain in the left leg; investigation showed that his seizures resulted from the rapid spread of epileptic discharges from his frontal lobes to the right anterior temporal region (96).

Of 718 patients investigated for intractable epilepsy with stereo-electroencephalography (SEEG), 30 (4%) manifested gustatory hallucinations as part of their seizures (77). Gustatory hallucinations, which occurred as one manifestation of parietal, temporal, or temporoparietal seizures, resulted from disorganization of the parietal or Rolandic operculum. Electrically induced seizures, which included a gustatory hallucination as an ictal event, occurred mainly with stimulation of the hippocampus and amygdala.

Selected cases with gustatory hallucinations indicate the range of lesions responsible:

	Temporal lobe epilepsy following seronegative limbic encephalitis. A 25-year-old man with drug-resistant temporal lobe epilepsy following seronegative limbic encephalitis related to non-Hodgkin lymphoma experienced musicogenic right temporal seizures triggered by listening to rock music; the seizures were characterized by déjà vu, piloerection, and gustatory hallucinations (149).
	Third-ventricular colloid cyst. A 46-year-old man experienced prolonged episodes of olfactory and gustatory hallucinations that abruptly resolved with stereotaxic aspiration of a third-ventricular colloid cyst (58).
	Partial status epilepticus, resulting from glioblastoma multiforme involving the hippocampus and amygdala. In one patient, new-onset olfactory and gustatory hallucinations were a presenting feature of partial status epilepticus resulting from a previously unrecognized glioblastoma multiforme involving the hippocampus and amygdala (29).
	Schizencephaly. A patient with schizencephaly and normal intelligence had frequent simple partial epileptic seizures with visual, auditory, and gustatory hallucinations (15).

In contrast to individuals with "purely temporal" epilepsies, those with "temporal plus" epilepsies--characterized by seizures involving a complex epileptogenic network including the temporal lobe and neighboring structures (eg, orbito-frontal cortex, insula, frontal and parietal opercula, and temporo-parieto-occipital junction)--more frequently have gustatory hallucinations, rotatory vertigo, and auditory illusions at seizure onset (12). Indeed, the most frequently reported auras among individuals with "purely temporal" epilepsies are gustatory hallucinations, vestibular illusions, laryngeal and throat constriction, and atypical somatosensory symptoms (perioral and bilateral acral paresthesias, etc.) (08).

Although déjà vu is common and qualitatively similar whether it occurs as an epileptic aura or as a normal phenomenon, patients with epilepsy are more likely to report olfactory and gustatory hallucinations, prior fatigue and concentrated activity, associated derealisation, fear, and physical symptoms such as headaches or abdominal sensations (213).

Although epileptic presentations of phantageusia are typically "irritative" hallucinations in Cogan's dichotomy of hallucinations, some cases of postictal phantageusia may instead represent "release" hallucinations akin to a Todd paralysis (42). For example, a 32-year-old man with epileptic seizures due to a grade 1 astrocytoma of the right sylvian region experienced gustatory hallucinations as a postictal symptom (07).

Olfactory and gustatory hallucinations in Parkinson disease. Bannier and colleagues reported that olfactory hallucinations occurred in 10% of the 87 patients with Parkinson disease in their series (11). Olfactory hallucinations were rare, short-duration, unpleasant odors that were not frightening and were recognized by the patients as hallucinations (like their visual hallucinations typically are recognized as unreal). Compared with controls, patients with Parkinson disease and olfactory hallucinations had olfactory impairment of both detection and identification, but there was no difference in their olfactory abilities compared with patients with Parkinson disease but no olfactory hallucinations.

Solla and colleagues similarly reported that olfactory hallucinations occur frequently in patients with Parkinson disease, particularly in women, and are often concomitant with visual and auditory hallucinations without any association with olfactory impairment (198). In a sample of 273 patients, 141 with Parkinson disease and 132 healthy controls of similar age, olfactory hallucinations were found in 11% of those with Parkinson disease and none of the controls (198). Among patients with Parkinson disease and olfactory hallucinations, 3% also had gustatory hallucinations (198). Visual or auditory hallucinations and female gender were independent predictors of olfactory hallucinations (198).

Other studies have reported lower frequencies of olfactory and gustatory hallucinations in patients with Parkinson disease. Holroyd and colleagues studied 98 patients with Parkinson disease, among which there were 26 with visual hallucinations, only one of which (1% of the total) was reported to have concomitant gustatory hallucinations, whereas none apparently had auditory, tactile, or olfactory hallucinations (89). None of the patients, therefore, had any unimodal hallucinations other than visual.

Olfactory and gustatory hallucinations in migraine. Olfactory and gustatory hallucinations occur occasionally in migraineurs (09; 150). Among 46 new female referrals for migraine headache, 15% reported olfactory or gustatory hallucinations and distortions of body image as part of most migraine attacks (150).

Olfactory and gustatory hallucinations in psychotic disorders. Among patients with schizophrenic or schizoaffective disorder, auditory hallucinations are by far the most common, followed by visual hallucinations and then by tactile and olfactory or gustatory hallucinations (152).

There are subgroups with psychosis that experience a higher frequency of olfactory and gustatory hallucinations. A subgroup of schizophrenia, characterized by premorbid eating disorders (ie, eating disorders preceding fulfillment of diagnostic criteria for schizophrenia), is more common in women and is associated with a higher frequency of gustatory hallucinations (135). In a sample of 36 patients with first-episode psychosis reporting nonauditory hallucinations and 31 controls from the same clinical population without nonauditory hallucinations, dissociation remained significantly associated with nonauditory hallucinations after adjusting for childhood sexual abuse, other types of childhood adversity, and emotional distress (131).

Tactile, olfactory, and gustatory hallucinations are often thought to be rare in primary psychotic illness. In a descriptive study of a large cohort of psychotic patients with schizophrenia, schizoaffective disorder, or bipolar I disorder, olfactory and gustatory hallucinations were present in 15% and 4% of the total sample, respectively (Table 2) (127). Hallucinations in the various sensory modalities occurred in patients across these diagnoses, and no modality-specific pattern is characteristic of a particular type of psychotic disorder. Tactile, olfactory, and gustatory hallucinations were associated with somatic delusions, delusions of control, thought broadcasting, earlier age at onset, and a lifetime history of depressive episodes (127).

Table 2. Frequency of Hallucinations by Modality in Patients with Psychotic Disorders

	Schizophrenia (n=133)	Schizoaffective (n=101)	Bipolar disorder (n=186)	Total Sample (n=420)
Auditory	76%	68%	27%	52%
Visual	24%	29%	16%	22%
Tactile	20%	21%	8%	15%
Olfactory	17%	23%	8%	15%
Gustatory	7%	2%	2%	4%
Total	79%	73%	41%	61%
From: (127)

In another cross-sectional study of 766 patients with adult psychotic disorders across the diagnostic categories of schizophrenia (n = 227), schizoaffective disorder (n = 210), and bipolar I disorder (n = 329), 26% had visual hallucinations (36). Visual hallucinations were independently associated with hallucinations in other modalities, history of a suicide attempt, catatonic behavior, and specific types of delusions (ie, delusions of control and religious, erotomanic, and jealousy delusions) (36).

In individuals with schizophrenia, referential or control delusions promote the generation or maintenance of olfactory hallucinations, which are associated with and frequently co-occur with hallucinations in other modalities, particularly somatic, tactile, and gustatory hallucinations (115). Olfactory hallucinations are also associated with social anxiety and depression in schizophrenics, with self-smells being particularly associated with self-deprecation (115).

Among 86 outpatients with DSM-IV delusional disorder, those with comorbid Axis I disorders (47%) had a fairly specific collection of additional features, which included more common olfactory and gustatory hallucinations, personality psychopathology, somatic delusions, and suicide risk (46); they also had more severe psychopathology, particularly in terms of emotional dysregulation. In contrast, those with delusional disorder without psychiatric comorbidity (ie, "pure" delusional disorder; 53%) had worse overall neurocognitive performance, mainly affecting working memory (46).

Among 43,339 patients with schizophreniform or affective disorder diagnoses, 0.54% had tactile hallucinations, 0.24% had olfactory hallucinations, and 0.06% had gustatory hallucinations (13). Tactile, olfactory, and gustatory hallucinations were associated with schizophreniform diagnosis, worse disorder severity, male gender, and black ethnicity (13). In fully adjusted multivariate statistical models, tactile and olfactory hallucinations were independently associated with prior mention of use of non-benzodiazepine hypnotics (“Z drugs,” such as zolpidem or zaleplon) (13).

Patients have been reported who were mistakenly thought to suffer from depression but actually had unnoticed drug-induced dysosmia and dysgeusia (125). Among individuals that superficially appear depressed, it is essential to distinguish (1) those with dysosmia or dysgeusia with reactive depressive manifestations and (2) those with primary neuropsychiatric illness with olfactory or gustatory hallucinations (125).

Prognosis and complications

Disorders of the chemosensory senses, smell and taste, are usually less disabling than disorders of the other special senses (vision and hearing). Nevertheless, chemosensory impairment adversely affects quality of life, and self-reported changes in flavor perception is a predictive factor for involuntary weight loss (158; 44). Taste and smell alterations are common in pediatric cancer patients due to chemotherapy (71; 210) and are associated with impaired nutritional status 6 months after chemotherapy (71).

Chemosensory dysfunction in COVID-19. COVID-19-associated chemosensory loss has a substantial negative impact on health-related quality of life beyond mere inconvenience (40; 55). Indeed, altered taste and smell with Covid-19 may cause severe disruption of daily living and quality of life that impacts psychological well-being, physical health, and interpersonal relationships (26; 40; 55). Affected individuals variously reported reduced desire and ability to eat and prepare food; weight gain, weight loss, and nutritional insufficiency; reduced emotional well-being; and impaired intimacy and social bonding (26; 68). "Reduced enjoyment of food" was the most common complaint (87%) in one study (40).

Among healthcare workers who contract COVID-19, olfactory and gustatory loss was associated with emotional distress, anxiety, and depression (52). Moreover, the psychological impact tends to persist even after recovery from the disease, adding to the risk of work-related distress (52).

The loss of smell and taste improves at a high rate after disease onset in most series (16; 66; 94; 137; 170; 25; 154; 178; 200; 205; 32; 38). However, a substantial proportion (approximately 4% to 5%) of patients with COVID-19 might develop long-lasting change in their sense of smell or taste (204). Rapid recovery of olfaction is observed in two thirds of COVID-19-infected people, but the remainder experience a slower pattern of recovery (108). By 1 month, almost all patients have a significant improvement in olfactory threshold and odor discrimination but not odor identification (94; 154). The recovery of gustation typically occurs before the recovery of olfaction (74). The mean duration of anosmia is 7 days (103), but many of these cases progress from anosmia to hyposmia and parosmia.

Nevertheless, some series report that between one third and one half of patients have persistent qualitative changes in olfaction (parosmia or phantosmia), typically accompanied by qualitative disorders of gustation (parageusia and phantageusia) (148; 57; 67; 90; 190; 134). Some experience long-term deficits with no self-reported improvement at 6 months (57; 67; 90). Persistent parosmia is common even in those who report at least some recovery of olfactory function (90).

Persistent loss of smell or taste was not associated with persistent SARS-CoV-2 infection (16).

Age younger than 40 years and presence of nasal congestion at the time of COVID-19 infection were associated with improved rates of smell recovery, whereas difficulty breathing at the time of COVID-19 infection and prior head trauma were associated with worsened rates of recovery (41).

Presbygeusia. Presbygeusia (literally “elderly taste” or “old-age taste”) is the gradual loss of taste that occurs in most people as they grow older. The elderly have higher detection and recognition thresholds for taste than younger individuals, and taste sensitivity is further compromised by medications and comorbid medical problems (185; 202). Healthy elderly people have higher thresholds for each taste category (sweet, sour, salty, bitter, and umami or savory), particularly for bitter substances, with the average threshold for taste rising fourfold in the elderly (62; 185; 202). The changes in taste sensitivity make food seem relatively tasteless and contribute to difficulties in complying with dietary regimens (such as a low-salt diet for the management of hypertension) (185).

Chemosensory deficits reduce the pleasure obtained from eating and represent risk factors for nutritional deficiencies and nonadherence to dietary regimens (53; 185). Lower olfactory perception in elderly women is associated with lower interest in food-related activities (such as cooking and eating a varied diet), a lower preference for foods with either a predominantly sour or bitter taste (such as citrus fruits) or pungency (such as horseradish), a higher intake of sweets, and a lower intake of low-fat milk products (53). Nutritional adequacy should be assessed in elderly women with a self-reported or measured difficulty in perceiving odors or flavor (53). Flavor-enhanced food positively affects food intake and can increase the enjoyment of food and improve the quality of life for elderly patients with chemosensory deficits (185). Flavor enhancements with simulated flavors can amplify odor intensity, improve the enjoyment of eating, and facilitate adequate nutrition in the elderly with hyposmia (but not anosmia) (185). Simulated flavors are mixtures of odoriferous substances that are either extracted from natural substances (as with concentrated orange juice or vanilla) or synthesized de novo (as with vanillin in artificial vanilla).

Burning mouth syndrome. Burning mouth syndrome is an uncommon painful intraoral disorder affecting mostly postmenopausal women (202). The pain is described as an uncomfortable, constant burning sensation in the mouth, affecting particularly the anterior tongue, palate, and lips. This may be associated with paresthesias or a numb sensation in the mouth or on the tip of the tongue, as well as a sensation of dry mouth and increased thirst without associated mucosal lesions. Approximately two thirds of affected individuals report dysgeusia or persistent abnormal taste sensations (which might be termed “palingeusia”) (202). Most have alterations in sensations of saltiness, and some have alterations in sweet, sour, and bitter tastes (202). The persistent taste sensations are most often described as bitter or metallic (torqugeusia) (202). Risk factors include older age, female gender, menopausal status, status as a “supertaster” (with a high-density of lingual papillae), upper respiratory infection, previous dental procedures, medications, traumatic life events, and stress (23). The etiology of burning mouth syndrome appears to be multifactorial; various conditions have been associated with it, including menopause, endocrine disorders (such as diabetes and hypothyroidism), nutritional disorders (such as deficiencies of iron, zinc, thiamine, riboflavin, pyridoxine, folate, and cobalamin), xerostomia (such as from Sjögren syndrome or other causes), medications (especially anticonvulsants and angiotensin-converting enzyme inhibitors), gastroesophageal reflux, postnasal drip, oral candidiasis, tongue plaque, removable dentures, halitosis, and mouth irritation (such as from overbrushing of the tongue, mouthwash, or acidic drinks) (202; 179). Many cases, however, are idiopathic. Burning mouth syndrome can be disabling and may cause various complications, including anorexia, weight loss, insomnia, irritability, depression, anxiety, and impaired socialization. The treatment depends on the etiology (if it can be identified). For primary (idiopathic) burning mouth syndrome, saliva-replacement products, oral rinses, clonazepam (applied topically or taken orally), gabapentin, selective serotonin reuptake inhibitor antidepressants, alpha-lipoic acid, B vitamins, and capsaicin have all been employed, with variable but limited success (although high-quality trials are lacking) (144; 222).

Psoriatic dysgeusia and burning mouth syndrome. Oral psoriasis is an overlooked cause of dysgeusia. Manifestations can include patches of red skin with yellow or white edges, sores, peeling skin on the gums, pustules, pain or burning (especially when eating spicy foods), fissured tongue, geographic tongue (red patches on the tongue resembling islands on a map), and swollen or infected gums.

Surface of psoriatic tongue, including a fungiform papilla (scanning electron micrograph) (1)

Image by David Gregory and Debbie Marshall. (Courtesy of the Wellcome Collection. Creative Commons Attribution 4.0 International [CC BY 4.0] License, https://creativecommons.org/licenses/by/4.0.)
Surface of psoriatic tongue, including a fungiform papilla (scanning electron micrograph) (2)

Image by David Gregory and Debbie Marshall. (Courtesy of the Wellcome Collection. Creative Commons Attribution 4.0 International [CC BY 4.0] License, https://creativecommons.org/licenses/by/4.0.)
Geographic tongue associated with oral psoriasis, and also diabetes and seborrheic dermatitis

A geographic tongue is often asymptomatic but may be associated with a burning sensation, especially with eating hot, acidic, and spicy foods. Photograph by Dimitrios Malamos on November 23, 2015. (Creative Commons Attribution ...

Clinical vignette. A 66-year-old patient presented to an oral medicine clinician with a 10-week history of “burning tongue, red at the tip, white bumps in the rear,” dysgeusia, and difficulty speaking (60). His physician had previously placed him on a nystatin topical rinse for 1 week without resolution. He had replaced his usual toothpaste with one that was supposedly free of the surfactant sodium lauryl sulfate. Eating spicy foods was not problematic. Pain was negligible on waking up but increased as the day progressed, although it did not interfere with his sleep. The patient was taking apixaban for atrial fibrillation, atorvastatin for cholesterol, lansoprazole for gastric reflux, fexofenadine and azelastine for seasonal allergies, and a vitamin D supplement. He had no known drug allergies. On examination, the anterior dorsal tongue was erythematous, but there was no lymphadenopathy or other abnormalities. He was referred to an allergist for food hypersensitivity, and the evaluation studies were negative. His symptoms seemed to improve after he eliminated paprika from his diet but then recurred.

Psoriatic dysgeusia and burning mouth syndrome: patient's tongue before treatment

(Source: Ferris WJ, Mikula S, Brown R, Farquharson A. Oral psoriasis of the tongue: a case report. Cureus 2019;11[12]:e6318. Creative Commons Attribution [CC BY 3.0] License, https://creativecommons.org/licenses/by/3.0.)

On biopsy, periodic acid-Schiff (PAS) staining showed candidiasis, and H&E staining at medium magnification demonstrated elongated rete pegs (ie, the epithelial extensions that project into the underlying connective tissue in both skin and mucous membranes, also known as rete processes or rete ridges).

Psoriatic dysgeusia and burning mouth syndrome: histopathology of the tongue with elongated rete pegs

(H&E, medium magnification) (Source: Ferris WJ, Mikula S, Brown R, Farquharson A. Oral psoriasis of the tongue: a case report. Cureus 2019;11[12]:e6318. Creative Commons Attribution [CC BY 3.0] License, https://creativecomm...

The papillary connective tissue was noted to show lymphocytic inflammation and dilated blood vessels approximating the epithelial margins. Lower magnification showed marked collections of neutrophils seen in the parakeratin, consistent with Munro microabscesses (ie, a cardinal sign of psoriasis where they are seen in the hyperkeratotic and parakeratotic areas of the stratum corneum). He was treated with of oral fluconazole 100 mg daily for 2 weeks, but his condition further deteriorated. A fungal DNA identification culture and sensitivity assay was negative for candida, aerobic, anaerobic, and acid-fast bacilli.

Psoriatic dysgeusia and burning mouth syndrome: worsening condition after treatment with antifungal

At this point, a consultant determined that the patient previously had been treated for cutaneous psoriasis that had begun in his teens with dry, red, blotchy lesions of the legs, trunk, and face. Calcipotriene ointment (a vitamin D analogue) for the trunk and leg lesions and desonide (a topical steroid) for the facial lesions had been sufficient to control the condition. The patient’s lesions subsequently resolved with a topical dexamethasone elixir rinse supporting a diagnosis of oral psoriasis. The steroid rinse was discontinued as a challenge, and in 2 weeks, the erythema and sensitivity returned. On resuming the topical steroid regimen, the lesions again resolved. A biological therapeutic was considered but deferred as the more conservative topical was effective.

Psoriatic dysgeusia and burning mouth syndrome: condition resolved with steroid treatment

(Source: Ferris WJ, Mikula S, Brown R, Farquharson A. Oral psoriasis of the tongue: a case report. Cureus 2019;11[12]:e6318. Creative Commons Attribution [CC BY 3.0] License, https://creativecommons.org/licenses/by/3.0.)
Psoriatic dysgeusia and burning mouth syndrome: condition returned after discontinuing steroid

(Source: Ferris WJ, Mikula S, Brown R, Farquharson A. Oral psoriasis of the tongue: a case report. Cureus 2019;11[12]:e6318. Creative Commons Attribution [CC BY 3.0] License, https://creativecommons.org/licenses/by/3.0.)

Cerebrovascular disease. Taste disorders are common, although underrecognized, in acute stroke, with hypogeusia occurring in approximately 30% of cases (79). Stroke-related hypogeusia is typically unilateral with brainstem strokes (113) but is strictly unilateral in only a minority of patients with cerebral infarction (79). Risk factors for stroke-associated gustatory loss include male gender, greater stroke-related functional impairment, dysphagia, and anterior circulation location, especially involving the peri-opercular frontal lobe (79). Interruption of the gustatory pathway in the brainstem usually occurs with lateral pontine stroke (113). Thalamic hypogeusia may be associated with a cheiro-oral syndrome (181). Stroke-related damage to the left insula causes an ipsilateral deficit in taste intensity but a bilateral deficit in taste recognition, suggesting that the left insula is dominant for taste recognition (165; 139). Stroke-associated dysgeusia and hypogeusia often persist, whereas other deficits improve and can contribute to unwanted weight loss poststroke (139; 61).

Alpha-synucleinopathies. Although less common than olfactory defects, impaired taste appreciation is also present in about a quarter of patients with clinically defined Parkinson disease, independent of age, disease severity, or olfactory deficits (189). Given the sparing of the first- and second-order taste neurons in Parkinson disease, a disorder of taste may indicate involvement of primary or secondary gustatory cortical areas, although confounding by drug effects (such as anticholinergic drugs) and changes in salivary constitution are possible (189).

Substance abuse. Taste detection and taste recognition thresholds of individuals with substance use disorder are impaired, and the threshold scores for sour, salty, sweet, and umami taste recognition are significantly lower compared with non-users (207).

Myasthenia gravis. Among 1688 patients with myasthenia gravis enrolled in a disease registry, 6% had taste disorders (208). Taste disorders were significantly more common in women, and those with severe symptoms, refractory myasthenia gravis, or thymoma-associated myasthenia gravis, and were less common with ocular myasthenia gravis (208). Taste disorders often occurred after the onset of myasthenia gravis and often responded to myasthenia gravis treatments (208).

Biological basis

Etiology and pathogenesis

	• Gustation, like disorders of the other special senses, can be conveniently divided into conductive, sensorineural, and central disorders, where (1) conductive disorders involve transmission of the sensory stimuli to the sensory receptors (usually but not always by impeding transmission); (2) sensorineural disorders involve dysfunction of the sensory receptors or conduction of signals from the sensory receptors to the brain; and (3) central disorders involve dysfunction of processing sensory information within the CNS, particularly within the brainstem and cerebrum.
	• Age-related gustatory loss (presbygeusia) is common in the elderly and results from normal aging, certain diseases (especially Parkinson disease and dementia with Lewy bodies), medications, surgical interventions, and prior environmental exposures.
	• The elderly have higher gustatory thresholds, perceive suprathreshold tastes less intensely, and are less able to discriminate tastants or recognize and identify common tastants.
	• COVID-19-related chemosensory dysfunction results primarily from a loss of function of olfactory sensory neurons and taste buds, mainly caused by infection, inflammation, and subsequent dysfunction of supporting non-neuronal cells in the mucosa.

Gustatory anatomy

The tongue and taste buds. Modern anatomical illustrations show the details of lingual anatomy clearly with labeling.

Distribution of various types of papillae on the human tongue

The sulcus terminans is located posterior to the vallate papillae and serves to separate the tongue from the lingual root. The root of the tongue, the "lingual tonsil," is free of papilla and instead has mucous glands and lymph...
Dissection of a human tongue

Illustration by Anatomist90 on April 16, 2013. (Creative Commons Attribution-Share Alike 3.0 Unported License, https://creativecommons.org/licenses/by-sa/3.0/deed.en.)

The tongue was very well illustrated at the beginning of the 19th century with clear anatomic drawings showing the angle of vallate papillae near the back of the tongue by German physician-anatomist Samuel Thomas von Sömmerring (1755-1830) (199). Still, even though some papillae were noticed and drawn, their function was not understood for about 60 years.

Anatomic drawing of the tongue

Legend: (K) filiform papillae, (I) fungiform papillae, (L) circumvallate papillae. This image was originally created in 1806, about 60 years before taste buds were recognized as gustatory organs. (Source: Hollis EW. A Text-Book...

Taste buds in humans were first independently described in 1868 by Swedish physician Otto Christian Lovén (1835-1904) and German anatomist Gustav Schwalbe (1844-1916) (133; 187; 188).

Swedish physician Otto Christian Lovén (1835-1904) c1897

From an album featuring portraits of all the members of the second chamber of the Swedish parliament elected in 1897. (Source: Wikimedia Commons. Public domain.)
German anatomist Gustav Schwalbe (1844-1916)

(Courtesy of the U.S. National Library of Medicine, Bethesda, Maryland. Public domain.)

They are bulb-shaped structures composed of about 50 to 120 bipolar cells. The average person has about 10,000 taste buds that are replaced approximately every 2 weeks.

Taste buds from a foliate papilla of a rabbit

(x850; Szymonowicz) (Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febiger, 1913.)
Transection of the medulla oblongata at about the middle of the olive

(Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febiger, 1913.)
Taste bud architecture (Graberg)

In the diagram, microvilli from gustatory cells are shown projecting into the "outer taste-pore." Also shown are peripheral and central supporting cells, lymphatic spaces, and a basal cell. (Source: Figure 1196 in: Piersol GA, ...
Pores in the tongue allow tastants to enter taste pores in the tongue

(Source: CNX OpenStax May 27, 2016. Modification of work by Vincenzo Rizzo. Creative Commons Attribution License [CC BY] License, https://creativecommons.org/licenses/by/4.0.)

Lingual papillae are small structures on the upper surface of the tongue that give it a rough texture. The four types of papillae on the human tongue have different structures and are accordingly classified as circumvallate (or vallate), fungiform, filiform, and foliate.

Four types of lingual papillae (diagram)

(Source: OpenStax textbook Anatomy and Physiology on May 18, 2016. Version 8.25, https://cnx.org/contents/FPtK1zmh@8.25:fEI3C8Ot@10/Preface. Creative Commons Attribution 4.0 International [CC BY 4.0] License, https://c...

The root of the tongue, the "lingual tonsil," is free of papillae and instead has mucous glands and lymphatic tissue. The large vallate papillae are positioned in a V-shaped array at the back of the tongue. The sulcus terminans is located posterior to the vallate papillae and serves to separate the tongue from the lingual root. From the vallate papillae posteriorly to the tip of the tongue, the tongue is covered in filiform and fungiform papillae.

All lingual papillae except the filiform papillae are associated with taste buds.

Sketch of a filiform papilla

(Source: Gray H, Lewis WH. Anatomy of the Human Body. Twentieth edition. Philadelphia and New York: Lea & Febiger, 1918. Public domain.)

Foliate papillae (without taste buds) were first reported in humans by German-born Dutch anatomist Bernhard Siegfried Albinus (originally Weiss; 1697-1770) in 1754 (04): they are located bilaterally along the posterolateral margins of the tongue surface and consist of parallel rows of ridges (folia) and valleys, which lie adjacent to the lower molar teeth (87).

German-born Dutch anatomist Bernhard Siegfried Albinus (originally Weiss, 1697-1770)

(Source: Dibner Library of the History of Science and Technology, Smithsonian Libraries. Public domain.)

Fungiform papillae have taste buds at the apex, whereas vallate and foliate papillae have taste buds arranged in arrays along the epithelial walls of the papillary trenches.

Section of a fungiform papilla

Magnified. (Source: Gray H, Lewis WH. Anatomy of the Human Body. Twentieth edition. Philadelphia and New York: Lea & Febiger, 1918. Public domain.)
Fungiform papillae on the mucous membrane of the tongue

Semidiagrammatic view of a portion of the mucous membrane of the tongue. Two fungiform papillae are shown. On some of the filiform papillae, the epithelial prolongations stand erect; in one they are spread out, and in three the...
Human fungiform papilla

Schematic drawing of a human fungiform papilla located on the tongue. Taste buds are indicated in brown. (Source: Illustration by Jonas Töle, 2014. Public domain dedication.)
Tongue, fungiform papilla

Scanning electron microscopic image by David Gregory and Debbie Marshall. (Courtesy of the Wellcome Collection, London, UK. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0...
Tongue, taste bud on fungiform papilla (1)

Scanning electron microscopic image by David Gregory and Debbie Marshall. (Courtesy of the Wellcome Collection, London, UK. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0...
Tongue, taste bud on fungiform papilla (2)

Scanning electron microscopic image by David Gregory and Debbie Marshall. (Courtesy of the Wellcome Collection, London, UK. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0...
Taste bud, close-up

Scanning electron microscopic image by David Gregory and Debbie Marshall. (Courtesy of the Wellcome Collection, London, UK. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0...
Circumvallate papilla in vertical section, showing arrangement of the taste-buds and nerves

(Source: Gray H, Lewis WH. Anatomy of the Human Body. Twentieth edition. Philadelphia and New York: Lea & Febiger, 1918. Public domain.)
Human vallate papilla located on the tongue

In the schematic drawing, taste buds are indicated in brown. (Source: Illustration by Jonas Töle, 2014. Public domain dedication.)

There are also extra-lingual taste buds embedded in the surface mucosa without papillae (eg, on the soft palate, oropharynx, epiglottis, and the upper esophagus).

Section of circumvallate papillae

(Source: Hollis EW. A Text-Book in General Physiology and Anatomy. New York, Cincinnati [etc.]: American Book Co., 1877.)
Circumvallate papillae: isolated taste bud, supporting or protecting cell, and taste cell

Legend: (A) isolated taste bud, from whose upper free end project the ends of the taste cells; (B) supporting or protecting cell; (C) taste cell. (Source: Hollis EW. A Text-Book in General Physiology and Anatomy. New York, Cinc...
Section of the foliate papillae papilla foliata of a rabbit, showing taste buds along the sides

(Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febiger, 1913.)
Vertical section of foliate papillae of the rabbit, passing across the folia (Ranvier)

The foliate papillae (papillae foliata) encompass numerous projections arranged in several transverse folds on the lateral lingual margins just anterior to the palatoglossal fold. (Source: Plate 1021 in: Gray H. Anatomy of the ...
Taste buds in section

Upper taste bud shows "gustatory hairs" (microvilli) projecting into the "pore canal" (x440). (Source: Piersol GA, Dwight T, McMurrich JP, Hamann CA, White JW. Human anatomy, including structure and development and practical co...
Transverse vertical section through papilla foliata of a 4-month-old infant

(x18) "The papillae foliatae, or gustatory lamellae of Turner, of the human tongue, offer an excellent area in which to study the taste-bulbs. They consist of five to eight irregular folds or ridges, with rounded or flattened c...
Histology of foliate papillae, showing taste buds (H&E)

(Source: Reytan on January 29, 2006, via Wikimedia Commons. Public domain.)

Sensorineural pathways. Three cranial nerves carry taste signals to the brainstem: the facial nerve (via the chorda tympani from the anterior two thirds of the tongue and via the greater petrosal nerve from the soft palate), the glossopharyngeal nerve (from the posterior one third of the tongue), and the vagus nerve (from a small area of the epiglottis).

Course and distribution of the glossopharyngeal, vagus, and spinal accessory nerves

The glossopharyngeal nerve mediates taste in the back third of the tongue. (Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febiger, 1913. The original figure has been...

The chorda tympani nerve arises from the mastoid segment of the facial nerve, carrying afferent special sensation from the anterior two thirds of the tongue via the lingual nerve (a sensory nerve that arises from the mandibular division of the trigeminal nerve) as well as efferent parasympathetic secretomotor innervation to the submandibular and sublingual glands.

Facial nerve and its branches (schematic diagram)

(Source: Romano N, Federici M, Castaldi A. Imaging of cranial nerves: a pictorial overview. Insights Imaging 2019;10[1]:33. Creative Commons Attribution 4.0 International [CC BY 4.0] License, https://creativecommons.org/license...

The chorda tympani nerve exits the cranial cavity through the internal acoustic meatus along with the facial nerve.

Chorda tympani nerve

A view of the right-sided middle ear space with the external ear canal, eardrum (tympanic membrane) and hearing bones (ossicles) removed, showing the course of the chorda tympani nerve. The observer is looking at the medial wal...

The chorda tympani nerve then accompanies the facial nerve inside the facial canal but separates before the stylomastoid foramen and travels through the middle ear, crossing behind the upper portion of the tympanic membrane on the medial surface of the neck of the malleus between the malleus and the incus.

Dissection of the facial nerve, showing the chorda tympani nerve

(Source: Anatomist90 on January 4, 2013. Creative Commons Attribution-Share Alike 3.0 Unported License, https://creativecommons.org/licenses/by-sa/3.0/deed.en.)
Course and connection of the facial nerve in the temporal bone

Note the chorda tympani nerve. (Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febiger, 1913.)
Drawing of the middle ear, showing the path of the chorda tympani nerve

This drawing of the middle ear, looking out toward the tympanic membrane, shows the path of the chorda tympani nerve. (Source: Gray H. Anatomy of the Human Body. Twentieth edition. Philadelphia and New York: Lea & ...
Normal right tympanic membrane showing chorda tympani nerve

Note the chorda tympani nerve passing lateral to the long process of the incus. Photograph by Dr. Michael Hawke on June 17, 2008. (Creative Commons Attribution 4.0 International [CC BY 4.0] License, https://creativecommons.org/...
Inner surface of the right tympanic membrane with the malleus and incus attached to each other (Politzer)

Legend: (a) short process of the incus; (pl) fold of the posterior pouch of the tympanic membrane; (ct) chorda tympani nerve; (h) head of the malleus; (n) niche in the outer wall of the tympanic cavity, in the squama. The fold ...

The chorda tympani nerve exits through the petrotympanic fissure and descends in the infratemporal fossa where it joins the larger lingual nerve (a branch of the mandibular nerve) (129).

Glossopalatine nerve (nervus intermedius) and the ganglionated cephalic plexus (diagram)

Each ganglion has three roots: the motor root is indicated by broken lines, the sensory root by dotted lines, and the sympathetic root solid lines. Mesial view, left side.

Legend: (c.a.) carotid artery; (c.g.) cil...
Plan of the facial and intermediate nerves and their communication with other nerves

(Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febiger, 1913.)
Sections of chorda tympani between the facial nerve and lingual nerve via the tympanic cavity

Section 1: mastoid process. Section 2: tympanic cavity. Section 3: submandibular fossa. (Source: Liu L, Arnold R, Robinson M. Dissection and exposure of the whole course of deep nerves in human head specimens after decalcificat...
Dissection of the whole chorda tympani nerve from facial nerve, passing through the tympanic cavity and joining the lingual nerve (Part I)

Legend: (VN) vestibular nerve, (FN) facial nerve, (S) stapes, (I) incus, (M) malleus, (CT) chorda tympani nerve, (GG) geniculate ganglion, (GPN) greater petrosal nerve, (CN) cochlear nerve, (PTF) petrotympanic fissure. (Source:...
Dissection of the whole chorda tympani nerve from facial nerve, passing through the tympanic cavity and joining the lingual nerve (Part II)

Legend: (FN) facial nerve, (I) incus, (M) malleus, (CT) chorda tympani nerve, (GG) geniculate ganglion, (GPN) greater petrosal nerve, (PTF) petrotympanic fissure, (LN) lingual nerve, (TM) tympanic membrane, (SF) stylomastoid fo...

Special sensory (taste) fibers extend from the chorda tympani to the anterior two thirds of the tongue via the lingual nerve. Fibers of the chorda tympani also travel with the lingual nerve to the submandibular ganglion, where preganglionic fibers of the chorda tympani synapse with postganglionic fibers that innervate the submandibular and sublingual salivary glands.

The cell bodies of the facial nerve associated with taste are located within the geniculate ganglion; the axons of these taste neurons enter the brainstem at the pontomedullary junction and travel caudally to the medulla oblongata, where they synapse at the nucleus solitarius.

Transection of the medulla oblongata at the lower end of the olives

(Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febiger, 1913.)
Transection of the medulla oblongata at about the middle of the olive

(Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febiger, 1913.)
Section of the medulla oblongata near the pons (Santee)

Legend: (a) hypoglossal nucleus; (b) vestibular nucleus; (c) tractus solitarius; (d) restiform body; (e) substantia reticularis; (f) hilus of olivary nucleus containing cerebello-olivary fibers; (g) anterior lateral sulcus; (h)...
Surface marking and topography of the principal nuclei of the floor of the fourth ventricle

(Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febiger, 1913.)
Cranial nerve nuclei schematically represented in a supposedly transparent brainstem, dorsal view

Motor nuclei in red; primary terminal nuclei of afferent nerves in blue. Optic and olfactory centers are omitted. (Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febi...
Primary terminal nuclei of afferent nerves schematically represented in a supposedly transparent brainstem, lateral view

The nucleus solitarius is in the area marked "IX and X" on the figure. Optic and olfactory centers are omitted. (Source: Gray H, Spitzka EA. Anatomy: Descriptive and Applied. Philadelphia and New York: Lea & Febige...

Despite anatomical evidence for the bilateral symmetry of the nerves innervating the tongue and the oral cavity (193), and despite focused studies of this issue beginning in the latter part of the 19th century and continuing to the present, the neural pathways to the gustatory cortices continue to be contested and remain unclear (70; 97; 192; 63; 64; 107; 01; 183; 195; 76; 159; 93). There is no consensus on whether the afferent taste information projects to the ipsilateral or contralateral gustatory cortex, or both, and at what level of the nervous system any crossing occurs (93).

One proposed framework for the taste pathways is as follows (193). Information derived from taste-responsive cranial nerves converges on the rostral division of the nucleus tractus solitarius (rNTS) in the medulla, the principal visceral-sensory nucleus of the brainstem. Fibers projecting from the rNTS join the central tegmental tract and synapse directly in the parvicellular part of the ventroposterior medial nucleus of the thalamus (VPMpc). Efferent fibers from VPMpc project to the primary gustatory cortex, the region of cerebral cortex responsible for the perception of taste and flavor; it is comprised of the anterior insula (of the insular lobe) and the frontal operculum (of the frontal lobe). The primary gustatory cortex sends projections to the central nucleus of the amygdala, and from there, gustatory information reaches the lateral hypothalamus and midbrain dopaminergic regions. The primary taste and olfactory cortices both project to a secondary gustatory cortex in the caudolateral orbitofrontal region. The lateral hypothalamus also projects to the orbitofrontal cortex, so taste responses can be modulated by satiety states. Finally, cortical taste areas send afferents to the rNTS and the gustatory parabrachial nuclei (PBN) of the pons, providing a means for top-down modulation of gustatory processing at the brainstem.

Available evidence indicates that (1) there is a relationship between handedness and gustatory processing; (2) the results of various studies are not consistent for different tastants; (3) asymmetries are evident in the CNS processing of gustatory information; (4) for right-handed individuals, there is a predominantly ipsilateral flow of taste information in the left-side pathway, especially for saltiness; (5) for right-handed individuals, taste information from the right oral cavity projects to the insula bilaterally; and (6) there is a direct input from the primary gustatory cortex in the left insula to the secondary gustatory cortex (93).

The left insula is predominantly activated by gustatory imagery tasks (105). In addition, the middle and superior frontal gyri participate in the generation of gustatory hallucinations but are not activated by gustatory perception; these regions of the frontal cortex may participate in "top-down" control of retrieving gustatory information from long-term memory (105).

Types of dysgeusia. Gustation, like disorders of hearing and the other special senses, can be conveniently divided into conductive, sensorineural, and central disorders, where (1) conductive disorders involve transmission of the sensory stimuli to the sensory receptors (usually but not always by impeding transmission); (2) sensorineural disorders involve dysfunction of the sensory receptors or conduction of signals from the sensory receptors to the brain; and (3) central disorders involve dysfunction of processing sensory information within the central nervous system, particularly within the brainstem and cerebrum.

Conductive gustatory disturbances. Conditions that impede or alter the contact of tastants with the taste receptors produce conductive (or “transport”) hypogeusia or dysgeusia. Such conditions can include poor oral hygiene, dental caries, periodontal disease, denture use, gastroesophageal reflux, upper respiratory infections, oral candidiasis (thrush), and oral cancer. With oral candidiasis, for example, the growth of yeast produces a barrier that precludes contact of the tastants with the gustatory receptors. Similarly, elderly patients frequently develop a thick, whitish mucoid coating on the tongue (“tongue plaque”), which is evident on arising and can interfere with taste acuity.

Conditions that interfere with chewing or salivation are also likely to produce conductive hypogeusia. During mastication, food is crushed and ground by the teeth (chewed), warmed, and mixed with liquid saliva. These actions release tastants from the food and facilitate the conveyance of tastants in a liquid or semiliquid state to the gustatory receptors (among other actions, such as facilitating enzymatic breakdown of food components). Therefore, conditions that interfere with chewing or movement of the food bolus (such as lack of teeth, poorly fitting dentures, temporomandibular joint dysfunction, jaw claudication, and dysphagia) can lessen the experience of taste.

Because saliva is necessary to help soften the masticated food and to convey tastants in a liquid state to the gustatory receptors, disorders that interfere with saliva production result in hypogeusia or dysgeusia. In addition, saliva helps to prevent pathologic growth of bacteria and fungi and to maintain oral pH and ionic composition at proper levels; disruption of any of these can alter taste sensation (202).

Saliva also modulates some long-lasting flavors by trapping free thiols produced by oral anaerobic bacteria (203). Bacteria convert odorless sulfur compounds in some fruits and vegetables (grapes, onions, and bell peppers) into odoriferous thiols after the foods had been swallowed (the so-called “retro-aromatic effect”). The odoriferous thiols can be perceived after 20 to 30 seconds and persist for several minutes.

Xerostomia (dry mouth due to a lack of saliva, sometimes colloquially called “cotton mouth” or “dough mouth”) is a common cause of conductive hypogeusia in the elderly. Xerostomia can occur with the use of various medications (such as anticholinergic medications and diuretics) and with tobacco smoking, diabetes mellitus, radiation therapy for head and neck cancers, and Sjögren syndrome (202).

Sensorineural and central gustatory disturbances. Taste sensations are mediated by polarized neuroepithelial cells that are clustered into taste buds scattered across the dorsal surface of the tongue and are present to a lesser degree on the soft palate, pharynx, epiglottis, larynx, and the first third of the esophagus. The facial (via the chorda tympani), glossopharyngeal, and vagus nerves transmit taste signals from the taste receptor cells to the rostral portion of the nucleus of the solitary tract in the dorsal medulla. Chemesthetic (pungent) sensations in the oral cavity are mediated separately via the trigeminal nerve and via free nerve endings in the chorda tympani, glossopharyngeal, and vagus nerves. Such sensations are a form of nociception distinct from taste (185).

From the nucleus of the solitary tract, taste-responsive axons project through the ipsilateral central tegmental tract in the pons, decussate at a higher level (probably in the midbrain), and project to the ventro-postero-medial nucleus of the thalamus and to other sites, including the lateral hypothalamus and the amygdala (122; 181). In the elderly, interruption of the central gustatory pathway in the brainstem most commonly results from lateral pontine strokes (181; 113). Gustatory neurons in the thalamus project to the primary gustatory cortex, which in humans has been tentatively localized to the transition area between the posterior insula and parietal operculum and the central sulcus (106). Cortical areas involved in processing gustatory stimuli are in the insula, the frontal and parietal opercula, and the orbitofrontal cortex (194). In right-handed individuals, the left cerebral hemisphere contains a gustatory representation of both sides of the tongue (hemi-tongues), whereas only the right hemi-tongue is represented in the right hemisphere (181; 139).

Severe symptomatic neural or central hypogeusia rarely occurs as a clinical entity, particularly in isolation. Nevertheless, sensorineural or central gustatory disorders can potentially result from damage to any part of the gustatory neural pathway from the tastebuds via the cranial nerves conveying gustatory sensation (the facial, glossopharyngeal, and vagal nerves) through the brainstem and thalamus to the cerebral cortex (78). Sensorineural and central gustatory disorders in the elderly may be caused by drugs, toxins, and physical agents; damage to the cranial nerves conveying gustatory sensation (for example, isolated cranial mononeuropathy as with Bell palsy, or cranial polyneuropathy); space-occupying processes (particularly with tumors involving the cerebellopontine angle or the jugular foramen); degenerative disorders (such as Parkinson disease or Alzheimer disease); seizures; and depression.

A systematic review and metaanalysis identified significant risks of gustatory dysfunction with Alzheimer disease, COVID-19, chemotherapy, and rhinosinusitis (132). Another systematic review and metaanalysis found that gustatory dysfunction has been inconsistently associated with Parkinson disease (112). Another systematic review and metaanalysis found that gustatory dysfunction diagnosed by gustatory function testing was closely associated with Alzheimer disease, even though the results of subjective questionnaires were not significantly different between patients with Alzheimer disease and healthy controls (111). Pooled analyses from a systematic review and metaanalysis showed worse global taste threshold and identification (sour in particular) scores in Alzheimer disease subjects than in controls and worse global, sweet, and sour scores in Alzheimer disease subjects compared to subjects with mild cognitive impairment (136). Subjects with Parkinson disease with mild cognitive impairment showed worse global, sweet, salty, and sour scores than controls and cognitively unimpaired subjects with Parkinson disease (136). Taste dysfunction is differentially associated with the severity of cognitive deficits regardless of the specific neurodegenerative disorders, suggesting that gustatory dysfunction may be a cross-disease chemosensory biomarker of neurocognitive disorders (141; 136). Whether gustatory alterations may be a useful preclinical biomarker of neurocognitive disorders requires further study.

Brain olfactory taste receptor (TASR) expression has been documented in neurologic diseases, including Alzheimer disease (06). TAS2R genes are expressed and markedly downregulated in human orbitofrontal cortex at early stages of sporadic Alzheimer disease, preceding the progressive reduction in their protein levels and the appearance of Alzheimer disease-associated neuropathology (06).

Types of phantageusia. In 1973, while trying to characterize the visual hallucinations observed among nonpsychotic patients with visual impairments, Harvard neuro-ophthalmologist David Cogan (1908-1993), then chairman of the Department of Ophthalmology at Harvard Medical School, usefully distinguished what he called “release” hallucinations from other types of hallucinations, particularly those associated with “irritative” processes in patients without psychosis (42). Shortly after this publication, Cogan left Harvard to become Chief of Neuro-ophthalmology at the National Eye Institute of the National Institutes of Health, Bethesda, Maryland.

David Cogan (1908-1993) at the National Eye Institute

(Courtesy of the National Eye Institute/National Institute of Health. Figure edited by Dr. Douglas J Lanska.)

Release hallucinations are spontaneous sensory phenomena that occur in the setting of sensory loss. Sufficient impairment or removal of normal afferent inputs to the primary visual cortex apparently allows, disinhibits, or “releases” spontaneous activity within the corresponding visual association cortex that is interpreted as a perception, even though there is no corresponding sensory stimulus (a hallucination). A release mechanism for hallucinations is supported by (1) a sensory deficit in the same modality as unimodal hallucinations, with onset of hallucinations in conjunction with or following the sensory deficit; (2) variable content; (3) awareness of the hallucinatory nature of the perception; and (4) no evidence of seizures or other irritative phenomena (including no other positive motor or sensory phenomena, not paroxysmal in character, no epileptiform discharges on electroencephalography, and unresponsive to administration of anticonvulsant medications) (42; 121; 120; 24; 116). Release hallucinations can occur in normal individuals with pansensory deprivation (84; 83). Similarly, modality-specific release hallucinations can occur experimentally (83; 143) or pathologically (80; 121; 120) with unimodal sensory deprivation.

In contrast, an “irritative” mechanism for hallucinations is supported by any of the following: (1) stereotyped content; (2) lack of awareness of the hallucinatory nature of the perception (termed hallucinosis); and (3) evidence of a potentially irritative process (such as migraine, tumor, or seizure) (42; 24). However, the clinical distinction between epileptic and release hallucinations is not always clear, and both types can occur in the same patient (Table 3). Spontaneous neuronal discharges, which can occur with both seizures and deafferentation, may be involved with both mechanisms (124; 54; 35).

Table 3. Comparison of Ictal and Release Visual Hallucinations

Characteristic	Ictal hallucinations	Release hallucinations
Duration	Brief (seconds to minutes)	Often persistent (minutes to hours)
Variability	Often stereotyped	Usually variable and change over time; rarely stereotyped
Content	Simple or complex	Simple or complex
Sensory deficit in modality of hallucination	No (except possibly incidental)	Yes
Environmental triggers	No	Common (low light, closing or opening eyes, saccadic eye movements)
Associated ictal behavior, including alterations of consciousness	Often	No
Epileptiform discharges or seizures demonstrated on EEG	Often	No
From: (42)

Cogan's dichotomy can usefully be applied to phantageusia but does not exhaust the possibilities. For example, it was never intended to encompass psychotic or psychogenic hallucinations or factitious disorder with pseudo-hallucinations.

Dysgeusia in COVID-19. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) enters human host cells via mechanisms facilitated by angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2). COVID-19-related chemosensory dysfunction results primarily from a loss of function of olfactory sensory neurons and taste buds, mainly caused by infection, inflammation, and subsequent dysfunction of supporting non-neuronal cells in the mucosa (138). COVID-19 entry receptors are highly expressed in taste buds, thereby intensifying the cytocidal effect.

The COVID-19-induced "cytokine storm" causes secondary damage to taste function, in part because interferon and various proinflammatory cytokines trigger cell apoptosis and disrupt the renewal of taste bud stem cells (211).

Interleukin 6 (IL-6), a pro-inflammatory cytokine that is promptly, but transiently, produced in response to infections and tissue injuries, contributes to host defense through the stimulation of acute-phase responses, hematopoiesis, and immune reactions. The rapid recovery of smell and taste functions in patients with COVID-19 may, in part, be attributable to changes in IL-6 levels rather than to recovery from viral injury to neurons (33; 200).

A high proportion of patients with COVID‐19 describe a loss of taste but standardized functional testing of the gustatory modalities of sweet, sour, salty, and bitter often do not reveal a bona fide hypogeusia (85; 146); therefore, subjectively altered taste is probably caused in part by impaired retronasal olfaction (85; 216; 146). Nevertheless, daily testing demonstrated that orthonasal smell, oral chemesthesis, and taste are each altered by acute SARS-CoV-2 infection; this disruption was dyssynchronous for different modalities, with variable loss and recovery rates across both modalities and individuals (215). Moreover, fungiform papillae biopsies on 16 patients who reported taste disturbance lasting more than 6 weeks after molecularly determined SARS-CoV-2 infection showed evidence of SARS-CoV-2, accompanying immune response, and misshapen or absent taste buds with loss of intergemmal neurite fibers (220).

Paxlovid mouth. The antiviral medication, Paxlovid (nirmatrelvir/ritonavir combination), has shown remarkable efficacy in reducing SARS-CoV-2 viral load and relieving clinical symptoms. However, a persistent bitter/bad taste, referred to as "Paxlovid mouth," is a frequent adverse effect, and this dysgeusia is listed as a main adverse effect of Paxlovid based on clinical trial data (30). Nirmatrelvir is an oral protease inhibitor that inhibits a SARS-CoV-2 protease (MPRO) that plays an essential role in viral replication, whereas ritonavir prolongs the activity of nirmatrelvir by slowing its metabolism; although ritonavir tastes bitter, prior usage of ritonavir in other conditions has not been linked to a persistent bad taste, suggesting that nirmatrelvir is responsible for Paxlovid mouth, possibly by activating one or more of the 25 human TAS2R bitter taste receptors. TAS2R1 is the primary bitter receptor activated by nirmatrelvir, at concentrations as low as 15 μM, which overlaps with plasma concentrations of nirmatrelvir in a subset of patients (30).

Epidemiology

	• There is a high prevalence of olfactory and gustatory dysfunction among patients with COVID-19.
	• Chemosensory disorders are relatively uncommon in pediatric cases of COVID-19 compared with adults.

Dysgeusia in COVID-19. There is a high prevalence of olfactory and gustatory dysfunction among patients infected with novel coronavirus disease 2019 (COVID-19) (02; 94; 10; 14; 178; 18; 22; 75; 98; 128; 153). Dysgeusia is more common in patients with COVID-19 than in those suffering from other viral infections or controls (164). In a meta-analysis of 24 studies collectively involving 8438 patients with test-confirmed COVID-19 infection from 13 countries, the pooled proportions of patients presenting with olfactory dysfunction and gustatory dysfunction were 41% and 38%, respectively (02). In a separate meta-analysis of eight studies, collectively involving 11,054 patients with COVID-19, dysosmia and dysgeusia symptoms were present in 75% and 81% cases of COVID-19, respectively (180). The prevalence of olfactory and gustatory dysfunction is negatively correlated with age in adults (02; 74; 123; 92; 157).

Chemosensory disorders are relatively uncommon in pediatric cases of COVID-19 compared with adults (56; 110; 166). In one series, only 6% of 122 pediatric COVID-19 cases had a chemosensory disorder, and all affected children fully recovered by the end of the third week of illness, even though one showed restricted diffusion in the splenium of the corpus callosum (56). In another series, 28% of 141 adolescents had chemosensory dysfunction with a self-reported duration of from 2 to 15 days (mean 5.7 days) (110).

Parageusia and dysfunctions in umami, bitter, and sweet taste perception can be indicators of more severe forms of COVID-19 (34).

The severity of COVID-19-associated chemosensory dysfunction has dropped significantly with the advent of the Omicron variant (18). Some studies also reported that the frequency of chemosensory dysfunction also declined with the advent of the Omicron variant; others found no change in the prevalence of chemosensory dysfunction during the period of Omicron dominance (201; 211). In one study in the Omicron era, individuals with chemosensory dysfunction had significantly higher rates of influenza-like upper respiratory symptoms, xerostomia, and halitosis (211). Moreover, olfactory dysfunction was a risk factor for the prevalence of taste dysfunction in patients with Omicron infection.

Differential diagnosis

Confusing conditions

When a patient presents with gustatory complaints, the critical considerations are determining whether there is a loss of function (hypogeusia or ageusia), a distortion of function (parageusia), or a perceived taste in the absence of a tastant in the mouth (phantageusia).

Reports of decreased ability to taste, or decreased ability to smell and taste, are often found to represent solely or primarily an impairment of olfaction. A bona fide hypogeusia should be categorized as conductive, sensorineural, or central as this will greatly focus the evaluation and the differential diagnosis. Acute bilateral impairment of smell and taste is likely related to an adverse drug reaction, an upper respiratory infection, or other viral illness (particularly SARS-CoV-2 during the COVID-19 pandemic). Acute unilateral impairment of taste is most commonly due to a facial nerve disorder (affecting the anterior two thirds of the tongue as in Bell palsy, Ramsay Hunt syndrome, Melkersson-Rosenthal syndrome, etc.) but can be seen also with glossopharyngeal nerve disorders (jugular foramen syndrome with unilateral loss of taste on the posterior third of the tongue), brainstem lesions (eg, cerebrovascular, demyelinating), and opercular lesions.

Distortions of function often accompany a loss of function, and most such distortions are unpleasant--often very unpleasant.

"Organic" phantageusias may occur by either an "irritative" mechanism (eg, epiliepsy, migraine) or a "release" mechanism (ie, in the setting of hypogeusia or ageusia or possibly postictally like a gustatory equivalent of a Todd paralysis). These must be distinguished from gustatory hallucinations that are manifestations of psychosis, psychogenic disorders, and factitious disorders.

Diagnostic workup

	• Medications that can alter gustatory function are numerous and varied.
	• Sudden onset of dysgeusia during the COVID-19 pandemic generally does not require extensive investigation.

Complaints of impaired “taste” are often symptoms of olfactory dysfunction because much of the flavor of a meal derives from olfactory stimulation. Indeed, the complex sensory experience of “flavor” during the consumption of foods and drinks cannot be constructed simply from combinations of the basic taste qualities (sweet, salty, sour, bitter, and umami or savory).

Review medications for medication-induced dysgeusia. Carefully review medications, including over-the-counter medications, for possible contributions to either olfactory or gustatory impairment. Medications that can alter taste in elderly patients are numerous and varied and include amitriptyline, baclofen, carbamazepine, phenytoin, levodopa, and propranolol as well as various lipid-lowering drugs, antihistamines, antimicrobials, antineoplastics, nonsteroidal anti-inflammatory drugs, allopurinol, bronchodilators and other asthma medications, antihypertensives and cardiac medications, lithium, antidepressants, and antipsychotics (175; 62; 185; 202; 48; 37). In the FDA Adverse Events Reporting System (FAERS), (1) gustatory adverse effects are more commonly reported than olfactory adverse effects; (2) antineoplastic and immunomodulating medications accounted for 22% and 36% of olfactory and gustatory adverse drug reactions; and (3) the angiogenesis inhibitor lenalidomide (for myelodysplastic syndrome, multiple myeloma, and mantle cell lymphoma) and the tyrosine kinase inhibitor antineoplastic agent sunitinib (for advanced or metastatic renal cancer, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors) were the drugs most commonly associated with gustatory dysfunction (45).

Dysgeusia in COVID-19. Sudden onset of dysgeusia during the COVID-19 pandemic generally does not require extensive investigation. New loss of taste (ageusia or hypogeusia) is now recognized as a COVID-19-related symptom, often but not always accompanied by dysosmia (eg, anosmia, hyposmia, or parosmia) (102; 137; 147; 172; 174; 155).

Toxin-induced chemosensory dysfunction. The neurologic history should address potential sources of toxin-induced chemosensory dysfunction, although toxin-induced chemosensory dysfunction is commonly associated with loss of smell rather than loss of taste (171; 196). Acute toxin-induced chemosensory loss may be straightforward if associated with a history of immediate-onset hyposmia or hypogeusia and a discrete toxin exposure, although confounding with litigation and financial incentives should be considered. In contrast, chronic exposures are typically more difficult to diagnose (171; 196).

Metabolic causes of taste dysfunction. Diabetes, hypothyroidism, kidney disease, and other metabolic conditions can cause dysgeusia, so screening studies should be done to identify or exclude these common disorders (142; 221).

Physical examination and office testing. Physical examination should include examination of the nose, mouth, and throat as well as neurologic examination.

Office testing of smell can include well-standardized, commercially available tests (such as the University of Pennsylvania Smell Identification Test, or UPSIT) or crude approaches utilizing identification of a few readily available odorants (such as oil of wintergreen or oil of cloves) (50; 51; 47; 48); more complicated odor identification and detection tests are also available but are rarely practical outside specialized diagnostic laboratories (47). The UPSIT is a forced-choice olfactory discrimination test that uses microencapsulated odorants in standardized “scratch ‘n’ sniff” booklets. UPSIT scores are standardized by gender and age and can be used to identify degrees of hyposmia and some malingerers. Irritant substances, such as ammonia, are sometimes employed when psychogenic or malingered anosmia is a consideration because such substances are perceived via trigeminal afferent pathways instead of through the olfactory system.

Office testing of gustatory function remains somewhat crude (186). Testing of taste thresholds is problematic because salivary function and size of the tongue area stimulated influence threshold assessment, taste intensity may be depressed even with normal recognition thresholds, and changes in threshold detection do not necessarily correlate with suprathreshold taste intensity. Nevertheless, complicated and time-consuming procedures are available for whole-mouth assessment of thresholds for each of the four primary tastes (sweet, sour, salty, and bitter) (218; 219) but are also rarely practical outside specialized diagnostic laboratories. Newer technologies, such as using flavor-impregnated taste strips or tasting tablets, are in development and can potentially include an assessment at multiple thresholds for all of the primary tastes, including umami (savory) gustatory sensation (03; 197; 114).

Special examination methods for assessing gustation. Chemical testing uses chemical tastants (eg, sucrose for sweet, citric acid for sour, sodium chloride for salty, caffeine for bitter, and monosodium glutamate for umami) to assess taste. Unfortunately, routine office testing of taste may not reveal any findings in transient, drug-induced taste disturbances. More complicated methods have been developed that can be used in office environments but that are more typically used in subspecialty clinics or research settings devoted to chemosensory disorders.

The 3-drop method of chemical testing is a subjective, non-localizing ("whole mouth") assessment technique that uses aqueous solutions of the five basic tastes to provide both the detection threshold (ie, the concentration at which the subject correctly identifies the presence of a taste) and the recognition threshold (ie, the concentration at which the subject correctly identifies the particular basic taste) (186; 214; 161). For each forced-choice trial of three separate drops (the two control drops being just water), the subject is asked to select the one that contains the tastant. Larger volumes can be used, in which case the subject must sip, swill, and spit. The tastant must be correctly identified three times, or else the next higher concentration solution is used. One potential confounding factor with this approach is that the aqueous solutions may wash away the saliva, the medium through which tastants are normally conveyed to taste buds, thus altering taste sensitivity (140). The use of tablets or wafers impregnated with the basic tastants eliminates some of the logistical challenges of using aqueous solutions of escalating concentration with controls; these can be easily stored and used for routine clinical practice but suffer the same drawbacks as any whole-mouth testing method (03; 186; 161).

Whole-mouth chemical testing methods are generally sufficient for drug-induced gustatory impairment, but, when necessary, regional chemical testing is possible with commercially available "Taste Strips," paper strips impregnated with one of four tastants (sweet, sour, salty, or bitter) in four different concentrations--16 separate strip types for all tastant-concentration combinations (151; 114; 186; 161). The Taste Strips are placed in a predetermined order on each side of the tongue while it is protruding from the mouth. Lateralizing hypogeusia is identified with side-to-side differences above an established threshold. Regional testing can be used to detect isolated lesions of the chorda tympani (anterior two thirds of the tongue) or glossopharyngeal nerve (posterior tongue).

Electrogustometry is a subjective, localizing assessment technique that uses a small electrical current (1.5 to 400 μA) from a monopolar or bipolar stimulator to assess "taste" detection thresholds in different parts of the tongue. This test can provide localizing information about gustatory deficits (186), but it cannot distinguish between the different qualities of flavor because electrical stimulation invariably elicits a metallic and sour "taste" sensation. Approximately half of the women who receive chemotherapy for gynecological cancer have abnormal electrogustometry test results, with a tendency to develop hypogeusia in the chorda tympani nerve field and hypergeusia in the greater petrosal nerve field (156). Both pathways are extensions of the facial nerve, but the chorda tympani originates from the taste buds in the front of the tongue, whereas the greater petrosal nerve (or greater superficial petrosal nerve) is a branch of the nervus intermedius (nerve of Wrisberg or glossopalatine nerve) that, among other things, carries taste afferents from the soft palate.

Gustatory evoked potentials are a feasible, objective assessment technique that can be used to distinguish ageusia from psychogenic disease or malingering (104; 95; 161). After the application of a chemical or electrical taste stimulus, evoked waveforms are recorded from an EEG. Unfortunately, gustatory evoked potentials may be influenced by various confounding factors (eg, thermal, tactile, or olfactory stimulation), are difficult to interpret, and only provide consistent results with sour tastes (161).

Imaging. Cranial imaging (CT and MRI) is most useful for patients with olfactory disorders to detect abnormalities in the nasal cavities (eg, nasal polyposis), nasal sinuses (eg, sinusitis), and anterior cranial fossa (eg, meningioma). They may rarely be useful in gustatory disorders, and there are almost always other neurologic signs that would indicate a central disorder.

Functional MRI and PET are not of clear clinical utility in the clinical evaluation of chemosensory disorders (181; 161).

Management

Management depends heavily on the responsible cause. Management action can improve or resolve dysgeusia with temporal lobe epilepsy and medication-induced dysgeusia.

Underlying olfactory disorders may cause secondary apparent decreased or altered taste sensations.

Burning mouth syndrome. Burning mouth syndrome has been treated with a wide range of drugs belonging to different pharmacological groups (eg, antidepressants, antipsychotics, antiepileptic drugs, analgesics, and mucosal protectors) (144). Although there are anecdotal reports of therapeutic success, an effective treatment modality for most cases of burning mouth syndrome remains to be established (144).

Conductive gustatory disturbances. Patients who have conductive gustatory disturbances due to a thick, whitish mucoid coating on the tongue (“tongue plaque”) should be encouraged to remove this with a soft toothbrush, with a dry gauze pad, or by eating so-called “detergent” foods (hard bread, dry cereal, uncooked vegetables, or fibrous meats). Tongue brushing should also be encouraged twice daily, on rising and before bed, especially in elderly patients with oral prostheses.

Breath mints, sugarless chewing gum or lozenges, artificial saliva products, citric acid mouthwashes, and systemic pilocarpine can each be of modest symptomatic benefit in patients with xerostomia.

Sensorineural and central gustatory disturbances. Sensorineural and central gustatory disturbances are generally much more difficult to manage.

Dysgeusia in COVID-19. A retrospective, hospital-based, observational study of 141 patients in Italy found that administration of steroids during the hospitalization was significantly associated with a higher chance of 3‐month recovery from chemosensory dysfunction (130)

Although systemic corticosteroids have been recommended as a therapeutic option in COVID-19-related chemosensory dysfunction, a more cautious approach is recommended until the results of randomized controlled trials are available (91). Reasons for not using systemic corticosteroids for COVID-19-associated chemosensory dysfunction include the following: (1) evidence supporting their usefulness is weak; (2) the rate of spontaneous recovery of COVID-19-related dysosmia is high; and (3) corticosteroids have significant potential adverse effects (91).

Media

References

01: Aglioti S, Tassinari G, Corballis MC, Berlucchi G. Incomplete gustatory lateralization as shown by analysis of taste discrimination after callosotomy. J Cogn Neurosci 2000;12(2):238-45. PMID 10771408
02: Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc 2020;95(8):1621-31. PMID 32753137
03: Ahne G, Erras A, Hummel T, Kobal G. Assessment of gustatory function by means of tasting tablets. Laryngoscope 2000;110(8):1396-401. PMID 10942148
04: Albinus BS. De fabrica papillarum linguae humanae. In: BS Albinus, editor. Academicarum annotationum libri I-VIII, Liber I, cap. XV. Leiden: J&H Verbeek Bibliopolas, 1754:59-63.
05: Al-Shouli ST, Meo SA, Alafaleq NO, et al. Prevalence of chemosensitive neurological disorders of smell and taste and association with blood groups in SARS-CoV-2 patients: cross-sectional study. Viruses 2023;15(6):1277. PMID 37376577
06: Alves VC, Figueiro-Silva J, Ferrer I, Carro E. Epigenetic silencing of OR and TAS2R genes expression in human orbitofrontal cortex at early stages of sporadic Alzheimer's disease. Cell Mol Life Sci 2023;80(8):196. PMID 37405535
07: Ambrosetto G. Post-ictal gustatory hallucination, sleep related microspikes and glioma of the sylvian region: report of a case. Clin Electroencephalogr 1986;17(2):89-91. PMID 3731501
08: Andrade-Machado R, Benjumea-Cuartas V. Temporal plus epilepsy: anatomo-electroclinical subtypes. Iran J Neurol 2016;15(3):153-63. PMID 27648177
09: Ardila A, Sanchez E. Neuropsychologic symptoms in the migraine syndrome. Cephalalgia 1988;8(2):67-70. PMID 3401918
10: Aziz M, Goyal H, Haghbin H, Lee-Smith WM, Gajendran M, Perisetti A. The association of "loss of smell" to COVID-19: a systematic review and meta-analysis. Am J Med Sci 2021;361(2):216-25. PMID 33349441
11: Bannier S, Berdagué JL, Rieu I, et al. Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83(10):1019-21. PMID 22752694
12: Barba C, Barbati G, Minotti L, Hoffmann D, Kahane P. Ictal clinical and scalp-EEG findings differentiating temporal lobe epilepsies from temporal “plus” epilepsies. Brain 2007;130(Pt 7):1957-67. PMID 17535836
13: Birnie KI, Stewart R, Kolliakou A. Recorded atypical hallucinations in psychotic and affective disorders and associations with non-benzodiazepine hypnotic use: the South London and Maudsley Case Register. BMJ Open 2018;8(9):e025216. PMID 30269078
14: Bianco MR, Modica DM, Drago GD, et al. Alteration of smell and taste in asymptomatic and symptomatic COVID-19 patients in Sicily, Italy. Ear Nose Throat J 2021;100(2_suppl):182S-5S. PMID 33350319
15: Bisgard C, Herning M. Severe schizencephaly without neurological abnormality. Seizure 1993;2(2):151-3. PMID 8167968
16: Boscolo-Rizzo P, Borsetto D, Fabbris C, et al. Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg 2020;146(8):729-32. PMID 32614442
17: Boscolo-Rizzo P, Hummel T, Invitto S, et al. Psychophysical assessment of olfactory and gustatory function in post-mild COVID-19 patients: A matched case-control study with 2-year follow-up. Int Forum Allergy Rhinol 2023a;13(10):1864-75. PMID 36852674
18: Boscolo-Rizzo P, Tirelli G, Meloni P, et al. Coronavirus disease 2019 (COVID-19)-related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) Omicron variant. Int Forum Allergy Rhinol 2022;12(10):1273-81. PMID 35286777
19: Boscolo-Rizzo P, Tirelli G, Meloni P, et al. Recovery from olfactory and gustatory dysfunction following COVID-19 acquired during Omicron BA.1 wave in Italy. Am J Otolaryngol 2023b;44(5):103944. PMID 37354725
20: Boscolo-Rizzo P, Spinato G, Hopkins C, et al. Evaluating long-term smell or taste dysfunction in mildly symptomatic COVID-19 patients: a 3-year follow-up study. Eur Arch Otorhinolaryngol 2023c;280(12):5625-30. PMID 37715807
21: Boscolo-Rizzo P, Hummel T, Spinato G, et al. Olfactory and gustatory function 3 years after mild COVID-19-A cohort psychophysical study. JAMA Otolaryngol Head Neck Surg 2024;150(1):79-81. PMID 37943538
22: Braga-Paz I, Ferreira de Araújo JL, Alves HJ, et al. Negative correlation between ACE2 gene expression levels and loss of taste in a cohort of COVID-19 hospitalized patients: new clues to long-term cognitive disorders. Front Cell Infect Microbiol 2022;12:905757. PMID 36250059
23: Brailo V, Vuéiaeeviae-Boras V, Alajbeg IZ, Alajbeg I, Lukenda J, Aeurkoviae M. Oral burning symptoms and burning mouth syndrome-significance of different variables in 150 patients. Med Oral Patol Oral Cir Bucal 2006;11(3):E252-5. PMID 16648763
24: Braun CM, Dumont M, Duval J, Hamel-Hébert I, Godbout L. Brain modules of hallucination: an analysis of multiple patients with brain lesions. J Psychiatry Neurosci 2003;28(6):432-49. PMID 14631455
25: Bulgurcu S, Öztutgan T, Baz E, et al. Assessment of smell and taste disorders in COVID-19: a cross-sectional study. J Craniofac Surg 2021;32(3):e298-301. PMID 33252531
26: Burges Watson DL, Campbell M, Hopkins C, Smith B, Kelly C, Deary V. Altered smell and taste: anosmia, parosmia and the impact of long Covid-19. PLoS One 2021;16(9):e0256998. PMID 34559820
27: Burnett CH, Ingals EF, Newcomb JE. A Text-Book on Diseases of the Ear, Nose and Throat. Philadelphia and London: JB Lippincott Company, 1901.
28: Cabrera CI, Hicks K, Rodriguez K, Gerka Stuyt JA, McComsey GA, D'Anza B. Comparison of the incidence of smell and taste disorders between influenza and COVID-19. Am J Otolaryngol 2024;45(3):104176. PMID 38157588
29: Capampangan DJ, Hoerth MT, Drazkowski JF, Lipinski CA. Olfactory and gustatory hallucinations presenting as partial status epilepticus because of glioblastoma multiforme. Ann Emerg Med 2010;56(4):374-7. PMID 20303620
30: Caronia L, Xi R, Margolskee RF, Jiang P. Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir. Biochem Biophys Res Commun 2023;682:138-40. PMID 37806252
31: Cattaneo C, Pagliarini E, Mambrini SP, et al. Changes in smell and taste perception related to COVID-19 infection: a case-control study. Sci Rep 2022;12(1):8192. PMID 35581235
32: Catton G, Gardner A. COVID-19 induced taste dysfunction and recovery: association with smell dysfunction and oral health behaviour. Medicina (Kaunas) 2022;58(6):715. PMID 35743978
33: Cazzolla AP, Lovero R, Lo Muzio L, et al. Taste and smell disorders in COVID-19 patients: role of interleukin-6. ACS Chem Neurosci 2020;11(17):2774-81. PMID 32786309
34: Cazzolla AP, Lovero R, Spirito F, et al. Evaluation of qualitative and quantitative taste alterations in COVID-19. Biomol Biomed 2023;23(2):344-50. PMID 35801415
35: Chattha AS, Lombroso CT. Electroencephalographic changes in childhood optic neuritis. Electroencephalogr Clin Neurophysiol 1972;33(1):81-8. PMID 4113277
36: Chouinard VA, Shinn AK, Valeri L, et al. Visual hallucinations associated with multimodal hallucinations, suicide attempts and morbidity of illness in psychotic disorders. Schizophr Res 2019;208:196-201. PMID 30842029
37: Chu SY, Wang HC, Hsieh MH, Chang CC. Taste disorder and tongue numbness after lithium overdose. Acta Neurol Taiwan 2024;33(4):185-7. PMID 38030229
38: Ciofalo A, Cavaliere C, Masieri S, et al. Long-term subjective and objective assessment of smell and taste in COVID-19. Cells 2022;11(5):788. PMID 35269410
39: Coelho DH, Kons ZA, Costanzo RM, Reiter ER. Subjective changes in smell and taste during the COVID-19 pandemic: a national survey-preliminary results. Otolaryngol Head Neck Surg 2020;163(2):302-6. PMID 32423359
40: Coelho DH, Reiter ER, Budd SG, Shin Y, Kons ZA, Costanzo RM. Quality of life and safety impact of COVID-19 associated smell and taste disturbances. Am J Otolaryngol 2021;42(4):103001. PMID 33773440
41: Coelho DH, Reiter ER, Budd SG, Shin Y, Kons ZA, Costanzo RM. Predictors of smell recovery in a nationwide prospective cohort of patients with COVID-19. Am J Otolaryngol 2022;43(1):103239. PMID 34547716
42: Cogan DG. Visual hallucinations as release phenomena. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1973;188(2):139-50.** PMID 4543235
43: D'Ascanio L, Pandolfini M, Cingolani C, et al. Olfactory dysfunction in COVID-19 patients: prevalence and prognosis for recovering sense of smell. Otolaryngol Head Neck Surg 2021;164(1):82-6. PMID 32662745
44: Daskalou D, Hsieh JW, Hugentobler M, et al. Predictive factors of involuntary weight loss in patients with smell and taste disorders. Rhinology 2024;62(2):163-71. PMID 37943027
45: Debbaneh P, McKinnon L, Haidari M, Liang J. Drug-induced olfactory and gustatory dysfunction: Analysis of FDA adverse events reporting system. Auris Nasus Larynx 2023;50(4):558-64. PMID 36682949
46: de Portugal E, Martinez C, González N, del Amo V, Haro JM, Cervilla JA. Clinical and cognitive correlates of psychiatric comorbidity in delusional disorder outpatients. Aust N Z J Psychiatry 2011;45(5):416-25. PMID 21417554
47: Doty RL. Office procedures for quantitative assessment of olfactory function. Am J Rhinol 2007;21(4):460-73. PMID 17882917
48: Doty RL. The Smell Identification Test Administration Manual. Haddon Heights, NJ: Sensonics, 2008.
49: Doty RL, Shah M, Bromley SM. Drug-induced taste disorders. Drug Saf 2008;31(3):199-215. PMID 18302445
50: Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984a;32(3):489-502. PMID 6463130
51: Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984b;94(2 Pt 1):176-8. PMID 6694486
52: Dudine L, Canaletti C, Giudici F, et al. Investigation on the loss of taste and smell and consequent psychological effects: a cross-sectional study on healthcare workers who contracted the COVID-19 infection. Front Public Health 2021;9:666442. PMID 34123991
53: Duffy VB, Backstrand JR, Ferris AM. Olfactory dysfunction and related nutritional risk in free-living, elderly women. J Am Diet Assoc 1995;95(8):879-84. PMID 7636078
54: Echlin FA, Battista A. Epileptiform seizures from chronic isolated cortex. Arch Neurol 1963;9:154-70. PMID 14048164
55: Elkholi SM, Abdelwahab MK, Abdelhafeez M. Impact of the smell loss on the quality of life and adopted coping strategies in COVID-19 patients. Eur Arch Otorhinolaryngol 2021;278(9):3307-14. PMID 33464401
56: Elmas B, Çavdaroğlu PD, Orhan MF, et al. Evaluation of taste and smell disorders in pediatric COVID-19 Cases. Rev Assoc Med Bras (1992) 2021;67(6):789-94. PMID 34709318
57: Ercoli T, Masala C, Pinna I, et al. Qualitative smell/taste disorders as sequelae of acute COVID-19. Neurol Sci 2021;42(12):4921-6. PMID 34557966
58: Faris AA, Terrence CF. Limbic system symptomatology associated with colloid cyst of the third ventricle. J Neurol 1989;236(1):60-1. PMID 2915231
59: Ferreira AMS, Nascimento JAD, Travassos LCP, Pernambuco LA. Olfactory and taste disorders in COVID-19: a cross-sectional study in primary health care. Rev Assoc Med Bras (1992) 2024;70(2):e20231018. PMID 38265352
60: Ferris WJ, Mikula S, Brown R, Farquharson A. Oral psoriasis of the tongue: a case report. Cureus 2019;11(12):e6318. PMID 31938609
61: Finsterer J, Stöllberger C, Kopsa W. Weight reduction due to stroke-induced dysgeusia. Eur Neurol 2004;51(1):47-9. PMID 14639032
62: Frank ME, Hettinger TP, Mott AE. The sense of taste: neurobiology, aging, and medication effects. Crit Rev Oral Biol Med 1992;3(4):371-93. PMID 1391417
63: Fujikane M, Nakazawa M, Ogasawara M, Hirata K, Tsudo N. [Unilateral gustatory disturbance by pontine infarction]. Rinsho Shinkeigaku 1998;38(4):342-3. PMID 9742885
64: Fujikane M, Itoh M, Nakazawa M, Yamaguchi Y, Hirata K, Tsudo N. [Cerebral infarction accompanied by dysgeusia--a clinical study on the gustatory pathway in the CNS]. Rinsho Shinkeigaku 1999;39(7):771-4. PMID 10548919
65: Fornazieri MA, Silva JLBD, Gameiro JG, et al. Chemosensory dysfunction 3-months after COVID-19, medications and factors associated with complete recovery. Ann Otol Rhinol Laryngol 2023;132(10):1177-85. PMID 36482672
66: Gelardi M, Trecca E, Cassano M, Ciprandi G. Smell and taste dysfunction during the COVID-19 outbreak: a preliminary report. Acta Biomed 2020;91(2):230-1. PMID 32420954
67: Gerkin RC, Ohla K, Veldhuizen MG, et al. Recent smell loss is the best predictor of COVID-19 among individuals with recent respiratory symptoms. Chem Senses 2021;46:bjaa081. PMID 33367502
68: Glezer I, Bruni-Cardoso A, Schechtman D, Malnic B. Viral infection and smell loss: the case of COVID-19. J Neurochem 2021;157(4):930-943. PMID 32970861
69: Gordon A. Diseases of the nervous system: for the general practitioner and student. Philadelphia: Blakiston's Son, 1913.
70: Goto N, Yamamoto T, Kaneko M, Tomita H. Primary pontine hemorrhage and gustatory disturbance: clinicoanatomic study. Stroke 1983;14(4):507-11. PMID 6658924
71: Grain A, Camuset M, Gras-Leguen C, Hardouin JB, Scherdel P, Caldari D. Taste and smell alterations affect nutritional status in children under chemotherapy. Acta Paediatr 2023;112(10):2231-8. PMID 37376794
72: Gray H. Anatomy of the Human Body. Twentieth edition. Philadelphia and New York: Lea & Febiger, 1918.
73: Gray H, Spitzka EA. Anatomy: descriptive and applied. Philadelphia and New York: Lea & Febiger, 1913.
74: Guillen Martinez A, Andreu Gálvez M, Rodríguez Sanz S, Hernández Ruiz P, García Morillas A, Esteban Sanchez T. Incidence of smell and taste disorders and associated factors in patients with mild to moderate COVID-19. Otolaryngol Pol 2020;75(2):1-5. PMID 33724231
75: Gusmao PAOA, Roveda JRC, Leite ASM, Leite AS, Marinho CC. Changes in olfaction and taste in patients hospitalized for COVID-19 and their relationship to patient evolution during hospitalization. Braz J Otorhinolaryngol 2022;88 Suppl 5(Suppl 5):S75-82. PMID 34876382
76: Hashimoto T, Doden T, Ono Y, Uematsu T. Bilateral hypogeusia caused by a small lesion in the lower midbrain tegmentum. BMJ Case Rep 2012;2012:bcr2012006837. PMID 22967685
77: Hausser-Hauw C, Bancaud J. Gustatory hallucinations in epileptic seizures. Electrophysiological, clinical and anatomical correlates. Brain 1987;110 (Pt 2):339-59. PMID 3105808
78: Heckmann JG, Lang CJ. Neurological causes of taste disorders. Adv Otorhinolaryngol 2006;63:255-64. PMID 16733343
79: Heckmann JG, Stössel C, Lang CJ, Neundörfer B, Tomandl B, Hummel T. Taste disorders in acute stroke: a prospective observational study on taste disorders in 102 stroke patients. Stroke 2005;36(8):1690-4. PMID 16002758
80: Henderson WR, Smyth GE. Phantom limbs. J Neurol Neurosurg Psychiatry 1948;11(2):88-112.** PMID 18861109
81: Henkin RI. Disorders of taste and smell. JAMA 1971;218(13):1946. PMID 5171076
82: Henkin RI. Metallic taste. JAMA 1993;270(11):1369-70. PMID 8360975
83: Heron W. The pathology of boredom. Sci Am 1957;196:52-56.**
84: Heron W, Doane BK, Scott TH. Visual disturbances after prolonged perceptual isolation. Can J Psychol 1956;10(1):13-8.** PMID 13293922
85: Hintschich CA, Wenzel JJ, Hummel T, et al. Psychophysical tests reveal impaired olfaction but preserved gustation in COVID-19 patients. Int Forum Allergy Rhinol 2020;10(9):1105-7. PMID 32613712
86: Hintschich CA, Niv MY, Hummel T. The taste of the pandemic-contemporary review on the current state of research on gustation in coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol 2022;12(2):210-16. PMID 34704387
87: Honigschmied J. Beiträge zur mikroskopischen Anatomie über die Geschmacksorgane der Säugethiere. Zeitschrift für wissenschaftliche Zoologie 1873;23:414-34.
88: Hollis EW. A Text-Book in General Physiology and Anatomy. New York, Cincinnati [etc.]: American book Co, 1877.
89: Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70(6):734-8. PMID 11385005
90: Horvath L, Lim JW, Taylor JW, et al. Smell and taste loss in COVID-19 patients: assessment outcomes in a Victorian [Australia] population. Acta Otolaryngol 2021;141(3):299-302. PMID 33307905
91: Huart C, Philpott CM, Altundag A, et al. Systemic corticosteroids in coronavirus disease 2019 (COVID-19)-related smell dysfunction: an international view. Int Forum Allergy Rhinol 2021;11(7):1041-6. PMID 33728824
92: Husain Q, Kokinakos K, Kuo YH, Zaidi F, Houston S, Shargorodsky J. Characteristics of COVID-19 smell and taste dysfunction in hospitalized patients. Am J Otolaryngol 2021;42(6):103068. PMID 33940252
93: Iannilli E, Gudziol V. Gustatory pathway in humans: a review of models of taste perception and their potential lateralization. J Neurosci Res 2019;97(3):230-40. PMID 30168865
94: Iannuzzi L, Salzo AE, Angarano G, et al. Gaining back what is lost: recovering the sense of smell in mild to moderate patients after COVID-19. Chem Senses 2020;45(9):875-81. PMID 33033827
95: Ikui A. A review of objective measures of gustatory function. Acta Otolaryngol Suppl 2002;(546):60-8. PMID 12132622
96: Inutsuka M, Ogino T, Yoshinaga H, Ohtsuka Y, Oka E. [A child with ictal fear as the primary epileptic manifestation]. No To Hattatsu 2003;35(4):336-41. PMID 12875212
97: Ito N, Suzuki N. [Ipsilateral gustatory disturbance by thalamic hemorrhage]. Rinsho Shinkeigaku 1993;33(5):559-61. PMID 8365066
98: Jain A, Kaur J, Kahlon N, et al. Sudden loss of smell and taste: clinical predictors of coronavirus disease 2019 infection. J Laryngol Otol 2022;136(8):747-9. PMID 35475481
99: Joffily L, Ungierowicz A, David AG, et al. The close relationship between sudden loss of smell and COVID-19. Braz J Otorhinolaryngol 2020;86(5):632-8. PMID 32561220
100: Jurisch A. Studien €uber die Papillae vallatae beim Menschen. Zeitschrift fur Anatomie und Entwicklungsgeschichte 1922;66:1-149.
101: Kang YJ, Cho JH, Lee MH, Kim YJ, Park CS. The diagnostic value of detecting sudden smell loss among asymptomatic COVID-19 patients in early stage: the possible early sign of COVID-19. Auris Nasus Larynx 2020;47(4):565-73. PMID 32553562
102: Kerslake R, Hall M, Randeva HS, et al. Co‑expression of peripheral olfactory receptors with SARS‑CoV‑2 infection mediators: potential implications beyond loss of smell as a COVID‑19 symptom. Int J Mol Med 2020;46(3):949-56. PMID 32705281
103: Klopfenstein T, Zahra H, Kadiane-Oussou NJ, et al. New loss of smell and taste: uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France. Int J Infect Dis 2020;100:117-22. PMID 32771635
104: Kobal G. Gustatory evoked potentials in man. Electroencephalogr Clin Neurophysiol 1985;62(6):449-54. PMID 2415341
105: Kobayashi M, Takeda M, Hattori N, et al. Functional imaging of gustatory perception and imagery: "top-down" processing of gustatory signals. Neuroimage 2004;23(4):1271-82. PMID 15589092
106: Kobayakawa T, Wakita M, Saito S, Gotow N, Sakai N, Ogawa H. Location of the primary gustatory area in humans and its properties, studied by magnetoencephalography. Chem Senses 2005;30 Suppl 1:i226-7. PMID 15738127
107: Kojima Y, Hirano T. [A case of gustatory disturbance caused by ipsilateral pontine hemorrhage]. Rinsho Shinkeigaku 1999;39(9):979-81. PMID 10614167
108: Konstantinidis I, Delides A, Tsakiropoulou E, Maragoudakis P, Sapounas S, Tsiodras S. Short-term follow-up of self-isolated COVID-19 patients with smell and taste dysfunction in Greece: two phenotypes of recovery. ORL J Otorhinolaryngol Relat Spec 2020;82(6):295-303. PMID 33049753
109: Kumar A, Maini K, Arya K, Sharma S. Simple Partial Seizure. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022. PMID 29763181
110: Kumar L, Kahlon N, Jain A, Kaur J, Singh M, Pandey AK. Loss of smell and taste in COVID-19 infection in adolescents. Int J Pediatr Otorhinolaryngol 2021;142:110626. PMID 33477014
111: Kwak IY, Kim KS, Min HJ. Association of gustatory dysfunction and Alzheimer. Rhinology 2024;62(2):130-42. PMID 37943054
112: Kwak IY, Kim KS, Min HJ. Gustatory dysfunction is related to Parkinson's disease: A systematic review and meta-analysis. Int Forum Allergy Rhinol 2023;13(10):1949-57. PMID 36934313
113: Landis BN, Leuchter I, San Millán Ruíz D, Lacroix JS, Landis T. Transient hemiageusia in cerebrovascular lateral pontine lesions. J Neurol Neurosurg Psychiatry 2006;77(5):680-3. PMID 16614035
114: Landis BN, Welge-Luessen A, Brämerson A, et al. "Taste Strips" - a rapid, lateralized, gustatory bedside identification test based on impregnated filter papers. J Neurol 2009;256(2):242-8. PMID 19221845
115: Langdon R, McGuire J, Stevenson R, Catts SV. Clinical correlates of olfactory hallucinations in schizophrenia. Br J Clin Psychol 2011;50(2):145-63. PMID 21545448
116: Lanska DJ. Disorders of the special senses in the elderly. In: Nair A, Sabbagh M, editors. Geriatric Neurology. Chichester, West Sussex, UK: John Wiley & Sons, 2014:396-459.**
117: Lanska DJ. Dissection of the brain in woodcut: a visual exploration of Renaissance anatomy from Gersdorff to Vesalius [Exhibition]. Lanska DJ, curator. Cleveland, OH: Dittrick Medical History Center, Case Western Reserve University, 2018.
118: Lanska DJ. The medieval cell doctrine: foundations, development, evolution, and graphic representations in printed books from 1490 to 1630. J Hist Neurosci 2022a;31(2-3):115-75.** PMID 34727005
119: Lanska DJ. Summarizing the medieval anatomy of the head and brain in a single image: Magnus Hundt (1501) and Johann Dryander (1537) as transitional pre-Vesalian anatomists. J Hist Neurosci 2022b;31(2-3):200-20.** PMID 34928780
120: Lanska DJ, Lanska MJ. Visual "release" hallucinations in juvenile neuronal ceroid-lipofuscinosis. Pediatr Neurol 1993;9(4):316-7.** PMID 8216547
121: Lanska DJ, Lanska MJ, Mendez MF. Brainstem auditory hallucinosis. Neurology. 1987;37(10):1685.** PMID 3658177
122: Lee BC, Hwang SH, Rison R, Chang GY. Central pathway of taste: clinical and MRI study. Eur Neurol 1998;39(4):200-3. PMID 9635469
123: Lee Y, Min P, Lee S, Kim SW. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci 2020;35(18):e174. PMID 32383370
124: Levison JD, Gibbs EL, Stillerman ML, Perlstein MA. Electroencephalogram and eye disorders: clinical correlation. Pediatrics 1951;7:422-7. PMID 14171534
125: Levenson JL. Dysosmia and dysgeusia presenting as depression. Gen Hosp Psychiatry 1985;7(2):171-3. PMID 3996907
126: Levy LM, Henkin RI. Brain gamma-aminobutyric acid levels are decreased in patients with phantageusia and phantosmia demonstrated by magnetic resonance spectroscopy. J Comput Assist Tomogr 2004;28(6):721-7. PMID 15538143
127: Lewandowski KE, DePaola J, Camsari GB, Cohen BM, Ongür D. Tactile, olfactory, and gustatory hallucinations in psychotic disorders: a descriptive study. Ann Acad Med Singap 2009;38(5):383-5. PMID 19521636
128: Lisan Q, Fieux M, Tran Khai N, Nevoux J, Papon JF. Prevalence and characteristics of altered sense of smell/taste during Covid-19 first wave: a French nationwide cross-sectional Study. Eur Ann Otorhinolaryngol Head Neck Dis 2022;139(1):9-12. PMID 34049827
129: Liu L, Arnold R, Robinson M. Dissection and exposure of the whole course of deep nerves in human head specimens after decalcification. Int J Otolaryngol 2012;2012:418650. PMID 22523494
130: Locatello LG, Trotta B, Bruno C, et al. Systemic steroids may enhance recovery from loss of smell and taste in hospitalized coronavirus disease 2019 (COVID-19) patients: an observational study. Int Forum Allergy Rhinol 2021;11(12):1689-93. PMID 34132052
131: Longden E, House AO, Waterman MG. Associations between nonauditory hallucinations, dissociation, and childhood adversity in first-episode psychosis. J Trauma Dissociation 2016;17(5):545-60. PMID 26913382
132: López-Salido SC, Espinoza-Gutiérrez HA, Housni FE, Flores-Soto ME, Viveros-Paredes JM. In health and illness: does taste remain consistent? Exploring the influence of inflammation on taste perception through a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2024;28(8):3085-98. PMID 38708467
133: Loven C. Beiträge zur Kenntniss vom Bau der Geschmackwärzchen der Zunge. Schultze's Archiv fUr Mikroskopische Anatomie 1868;4:96-110.
134: Ludwig S, Schell A, Berkemann M, et al. Post-COVID-19 impairment of the senses of smell, taste, hearing, and balance. Viruses 2022;14(5):849. PMID 35632590
135: Malaspina D, Walsh-Messinger J, Brunner A, et al. Features of schizophrenia following premorbid eating disorders. Psychiatry Res 2019;278:275-80. PMID 31254876
136: Mantovani E, Zanini A, Cecchini MP, Tamburin S. The association between neurocognitive disorders and gustatory dysfunction: a systematic review and meta-analysis. Neuropsychol Rev 2024;34(1):192-213. PMID 36806051
137: Martin-Sanz E, Riestra J, Yebra L, et al. Prospective study in 355 patients with suspected COVID-19 infection: value of cough, subjective hyposmia, and hypogeusia. Laryngoscope 2020;130(11):2674-9. PMID 32686164
138: Mastrangelo A, Bonato M, Cinque P. Smell and taste disorders in COVID-19: from pathogenesis to clinical features and outcomes. Neurosci Lett 2021;748:135694. PMID 33600902
139: Mathy I, Dupuis MJ, Pigeolet Y, Jacquerye P. Agueusie bilatérale après accident vasculaire cérébral ischémique insulaire et operculaire gauche [Bilateral ageusia after left insular and opercular ischemic stroke]. Rev Neurol (Paris) 2003;159(5 Pt 1):563-7. PMID 12773901
140: Matsuo R. Role of saliva in the maintenance of taste sensitivity. Crit Rev Oral Biol Med 2000;11(2):216-29. PMID 12002816
141: Mattos JL, Hasan S, Schlosser RJ, Payne SC, Soler ZM. The association of gustatory dysfunction, olfactory dysfunction, and cognition in older adults. Int Forum Allergy Rhinol 2023;13(9):1577-83. PMID 36562185
142: McConnell RJ, Menendez CE, Smith FR, Henkin RI, Rivlin RS. Defects of taste and smell in patients with hypothyroidism. Am J Med 1975;59(3):354-64. PMID 1163545
143: Melzack R, Bromage PR. Experimental phantom limbs. Exp Neurol 1973;39(2):261-9.** PMID 4702820
144: Minguez Serra MP, Salort Llorca C, Silvestre Donat FJ. Pharmacological treatment of burning mouth syndrome: a review and update. Med Oral Patol Oral Cir Bucal 2007;12(4):E299-304. PMID 17664916
145: Mitchell MB, Workman AD, Rathi VK, Bhattacharyya N. Smell and taste loss associated with COVID-19 infection. Laryngoscope 2023;133(9):2357-61. PMID 37265267
146: Miwa T, Mori E, Sekine R, et al. Olfactory and taste dysfunctions caused by COVID-19: a nationwide study. Rhinology 2023;61(6):552-60. PMID 37690065
147: Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol 2020a;10(8):944-50. PMID 32301284
148: Moein ST, Hashemian SM, Tabarsi P, Doty RL. Prevalence and reversibility of smell dysfunction measured psychophysically in a cohort of COVID-19 patients. Int Forum Allergy Rhinol 2020b;10(10):1127-35. PMID 32761796
149: Morano A, Orlando B, Fanella M, et al. Musicogenic epilepsy in paraneoplastic limbic encephalitis: a video-EEG case report. Epileptic Disord 2021;23(5):754-9. PMID 34612817
150: Morrison DP. Abnormal perceptual experiences in migraine. Cephalalgia 1990;10(6):273-7. PMID 2289227
151: Mueller C, Kallert S, Renner B, et al. Quantitative assessment of gustatory function in a clinical context using impregnated "taste strips." Rhinology 2003;41(1):2-6. PMID 12677732
152: Mueser KT, Bellack AS, Brady EU. Hallucinations in schizophrenia. Acta Psychiatr Scand 1990;82(1):26-9. PMID 2399817
153: Nanjo Y, Okuma T, Kuroda Y, et al. Multiple types of taste disorders among patients with COVID-19. Intern Med 2022;61(14):2127-34. PMID 35527025
154: Niklassen AS, Draf J, Huart C, et al. COVID-19: recovery from chemosensory dysfunction. a multicentre study on smell and taste. Laryngoscope 2021;131(5):1095-100. PMID 33404079
155: Ninchritz-Becerra E, Soriano-Reixach MM, Mayo-Yánez M, et al. Subjective evaluation of smell and taste dysfunction in patients with mild COVID-19 in Spain. Med Clin (Barc) 2021;156(2):61-4. PMID 33168151
156: Nishijima S, Yanase T, Tsuneki I, Tamura M, Kurabayashi T. Examination of the taste disorder associated with gynecological cancer chemotherapy. Gynecol Oncol 2013;131(3):674-8. PMID 24060414
157: Nouchi A, Chastang J, Miyara M, et al. Prevalence of hyposmia and hypogeusia in 390 COVID-19 hospitalized patients and outpatients: a cross-sectional study. Eur J Clin Microbiol Infect Dis 2021;40(4):691-7. PMID 33033955
158: O'Donoghue A, Barrett M, Dhuibhir PU, Kennedy A, O'Leary N, Walsh D. Taste and smell abnormalities in advanced cancer: Negative impact on subjective food intake. Nutr Clin Pract 2023;38(4):807-16. PMID 36617307
159: Onoda K, Ikeda M, Sekine H, Ogawa H. Clinical study of central taste disorders and discussion of the central gustatory pathway. J Neurol 2012;259(2):261-6. PMID 21748279
160: Paderno A, Schreiber A, Grammatica A, et al. Smell and taste alterations in COVID-19: a cross-sectional analysis of different cohorts. Int Forum Allergy Rhinol 2020;10(8):955-62. PMID 32410386
161: Payne T, Kronenbuerger M, Wong G. Gustatory testing. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022. PMID 33620811
162: Piersol GA, Dwight T, McMurrich JP, Hamann CA, White JW. Human anatomy, including structure and development and practical considerations. Piersol GA, editor. Vol. II. Philadelphia & London: JB Lippincott Company, 1911.
163: Piu N, Isabella A, Airoldi C, Aleni C, Sarro A, Faggiano F. Taste and smell disorders in COVID-19 patients at a local healthcare trust in Northern Italy: a cross-sectional study. Ann Ig 2022;34(2):122-7. PMID 35088821
164: Printza A, Constantinidis J. The role of self-reported smell and taste disorders in suspected COVID‑19. Eur Arch Otorhinolaryngol 2020;277(9):2625-30. PMID 32447496
165: Pritchard TC, Macaluso DA, Eslinger PJ. Taste perception in patients with insular cortex lesions. Behav Neurosci 1999;113(4):663-71. PMID 10495075
166: Pua Torrejon RC, Ordoño Saiz MV, González Alguacil E, et al. Smell and taste dysfunction in pediatric patients with SARS-CoV-2 infection. Pediatr Neurol 2022;136:28-33. PMID 36084419
167: Purja S, Shin H, Lee JY, Kim E. Is loss of smell an early predictor of COVID-19 severity: a systematic review and meta-analysis. Arch Pharm Res 2021;44(7):725-40. PMID 34302637
168: Rass V, Tymoszuk P, Sahanic S, et al. Distinct smell and taste disorder phenotype of post-acute COVID-19 sequelae. Eur Arch Otorhinolaryngol 2023;280(11):5115-28. PMID 37670171
169: Reiter ER, Coelho DH, French E, Costanzo RM, N3C Consortium. COVID-19-Associated Chemosensory Loss Continues to Decline. Otolaryngol Head Neck Surg 2023;169(5):1386-9. PMID 37232470
170: Reiter ER, Coelho DH, Kons ZA, Costanzo RM. Subjective smell and taste changes during the COVID-19 pandemic: short term recovery. Am J Otolaryngol 2020;41(6):102639. PMID 32682192
171: Reiter ER, DiNardo LJ, Costanzo RM. Toxic effects on gustatory function. Adv Otorhinolaryngol 2006;63:265-77. PMID 16733344
172: Rocke J, Hopkins C, Philpott C, Kumar N. Is loss of sense of smell a diagnostic marker in COVID-19: a systematic review and meta-analysis. Clin Otolaryngol 2020;45(6):914-22. PMID 32741085
173: Rogn A, Jensen JL, Iversen PO, Singh PB. Post-COVID-19 patients suffer from chemosensory, trigeminal, and salivary dysfunctions. Sci Rep 2024;14(1):3455. Erratum in: Sci Rep 2024;14(1):9213. PMID 38342941
174: Roland LT, Gurrola JG, Loftus PA, Cheung SW, Chang JL. Smell and taste symptom-based predictive model for COVID-19 diagnosis. Int Forum Allergy Rhinol 2020;10(7):832-38. PMID 32363809
175: Rollin H. Drug-related gustatory disorders. Ann Otol Rhinol Laryngol 1978;87:37-42. PMID 623418
176: Romano N, Federici M, Castaldi A. Imaging of cranial nerves: a pictorial overview. Insights Imaging 2019;10(1):33. PMID 30877408
177: Sakalli E, Temirbekov D, Bayri E, Alis EE, Erdurak SC, Bayraktaroglu M. Ear nose throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients. Am J Otolaryngol 2020;41(6):102622. PMID 32629147
178: Salcan I, Karakeçili F, Salcan S, et al. Is taste and smell impairment irreversible in COVID-19 patients? Eur Arch Otorhinolaryngol 2021;278(2):411-5. PMID 33432396
179: Salort-Llorca C, Mínguez-Serra MP, Silvestre FJ. Drug-induced burning mouth syndrome: a new etiological diagnosis. Med Oral Patol Oral Cir Bucal 2008;13(3):E167-70. PMID 18305436
180: Samaranayake LP, Fakhruddin KS, Panduwawala C. Sudden onset, acute loss of taste and smell in coronavirus disease 2019 (COVID-19): a systematic review. Acta Odontol Scand 2020;78(6):467-73. PMID 32762282
181: Sanchez-Juan P, Combarros O. Síndromes lesionales de las vías nerviosas gustativas [Gustatory nervous pathway syndromes]. Neurologia 2001;16(6):262-71. PMID 11423043
182: Santos RE, da Silva MG, do Monte Silva MC, et al. Onset and duration of symptoms of loss of smell/taste in patients with COVID-19: a systematic review. Am J Otolaryngol 2021;42(2):102889. PMID 33445036
183: Sato K, Nitta E. [A case of ipsilateral ageusia, sensorineural hearing loss and facial sensorimotor disturbance due to pontine lesion]. Rinsho Shinkeigaku 2000;40(5):487-9. PMID 11002734
184: Sayin P, Altinay M, Cinar AS, Ozdemir HM. Taste and smell impairment in critically ill patients with COVID-19: an intensive care unit study. Ear Nose Throat J 2021;100(2_suppl):174S-9S. PMID 33258690
185: Schiffman SS. Taste and smell losses in normal aging and disease. JAMA 1997;278(16):1357-62. PMID 9343468
186: Schuster B, Iannilli E, Gudziol V, Landis BN. Gustatory testing for clinicians. B-ENT 2009;5 Suppl 13:109-13. PMID 20084811
187: Schwalbe G. Ueber die Geschmacksorgane der Säugethiere und des Menschen. Archiv für mikroskopische Anatomie 1868a;4:154-87.
188: Schwalbe G. Zur Kennthiss der Papillae funiformes des Säugethiere. Centralblatt für die medicinischen Wissenschaften 1868b;6:433-4.
189: Shah M, Deeb J, Fernando M, et al. Abnormality of taste and smell in Parkinson's disease. Parkinsonism Relat Disord 2009;15(3):232-7. PMID 18606556
190: Shahrvini B, Prajapati DP, Said M, et al. Risk factors and characteristics associated with persistent smell loss in coronavirus disease 2019 (COVID-19) patients. Int Forum Allergy Rhinol 2021;11(8):1280-2. PMID 33864717
191: Sharetts R, Moein ST, Khan R, Doty RL. Long-term taste and smell outcomes after COVID-19. JAMA Netw Open 2024;7(4):e247818. PMID 38652477
192: Shikama Y, Kato T, Nagaoka U, et al. Localization of the gustatory pathway in the human midbrain. Neurosci Lett 1996;218(3):198-200. PMID 8945762
193: Simon SA, de Araujo IE, Gutierrez R, Nicolelis MA. The neural mechanisms of gustation: a distributed processing code. Nat Rev Neurosci 2006;7(11):890-901.** PMID 17053812
194: Small DM, Zald DH, Jones-Gotman M, et al. Human cortical gustatory areas: a review of functional neuroimaging data. Neuroreport 1999;10(1):7-14. PMID 10094124
195: Small DM. Central gustatory processing in humans. Adv Otorhinolaryngol 2006;63:191-220. PMID 16733340
196: Smith WM, Davidson TM, Murphy C. Toxin-induced chemosensory dysfunction: a case series and review. Am J Rhinol Allergy 2009;23(6):578-81. PMID 19958605
197: Smutzer G, Lam S, Hastings L, et al. A test for measuring gustatory function. Laryngoscope 2008;118(8):1411-6. PMID 18528309
198: Solla P, Masala C, Pinna I, et al. Frequency and determinants of olfactory hallucinations in Parkinson's disease patients. Brain Sci 2021;11(7):841. PMID 34202903
199: Sommerring ST. Abbildungen der menschlichen Organe des Geschmackes und der Stimme. Frankfurt am Main: Varrentrapp und Wenner, 1806.
200: Song J, Deng YK, Wang H, et al. Self-reported taste and smell disorders in patients with COVID-19: distinct features in China. Curr Med Sci 2021;41(1):14-23. PMID 33582900
201: Song J, Jing Q, Zhu E, et al. Alterations in smell or taste in individuals infected with SARS-CoV-2 during periods of Omicron variant dominance. Int J Infect Dis 2023;128:278-84. PMID 36657518
202: Spielman AI. Chemosensory function and dysfunction. Crit Rev Oral Biol Med 1998;9(3):267-91. PMID 9715366
203: Starkenmann C, Le Calvé B, Niclass Y, Cayeux I, Beccucci S, Troccaz M. Olfactory perception of cysteine-S-conjugates from fruits and vegetables. J Agric Food Chem 2008;56(20):9575-80. PMID 18811169
204: Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ 2022;378:e069503. PMID 35896188
205: Tarifi A, Al Shdaifat AA, Al-Shudifat AM, et al. Clinical, sinonasal, and long-term smell and taste outcomes in mildly symptomatic COVID-19 patients. Int J Clin Pract 2021;75(7):e14260. PMID 33884722
206: Tuckerman F. The anatomy of the papilla foliata of the human infant. J Anat Physiol 1888;22(New Series Vol. 2):499-501.
207: Urhan M, Gezmen Karadag M. Diet quality, nutritional status and taste recognition are impaired in men with substance use disorder. Nutr Bull 2024;49(1):40-51. PMID 38115211
208: Uzawa A, Suzuki S, Kuwabara S, et al. Taste disorders and alopecia in myasthenia gravis. BMC Neurol 2024;24(1):139. PMID 38664714
209: Vaira LA, De Vito A, Lechien JR, et al. New onset of smell and taste loss are common findings also in patients with symptomatic COVID-19 after complete vaccination. Laryngoscope 2022;132(2):419-21. PMID 34812498
210: van den Brink M, Havermans RC, Fiocco M, Tissing WJE. A longitudinal evaluation of smell and taste function in children with cancer during and after treatment with chemotherapy. Appetite 2024;193:107174. PMID 38128763
211: Wang J, Chen Y, Huang J, et al. Prevalence of taste and smell dysfunction in mild and asymptomatic COVID-19 patients during Omicron prevalent period in Shanghai, China: a cross-sectional survey study. BMJ Open 2023;13(3):e067065. PMID 36944468
212: Wang J, Liu R, Ma H, Zhang W. The pathogenesis of COVID-19-related taste disorder and treatments. J Dent Res 2023;102(11):1191-8. PMID 37729625
213: Warren-Gash C, Zeman A. Is there anything distinctive about epileptic deja vu? J Neurol Neurosurg Psychiatry 2014;85(2):143-7. PMID 23315620
214: Webb J, Bolhuis DP, Cicerale S, Hayes JE, Keast R. The relationships between common measurements of taste function. Chemosens Percept 2015;8(1):11-8. PMID 26110045
215: Weir EM, Exten C, Gerkin RC, Munger SD, Hayes JE. Transient loss and recovery of oral chemesthesis, taste and smell with COVID-19: A small case-control series. Physiol Behav 2023;271:114331. PMID 37595820
216: Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA 2020;323(24):2512-4. PMID 32432682
217: Witt M. Anatomy and development of the human taste system. Handb Clin Neurol 2019;164:147-71.** PMID 31604544
218: Yamauchi Y, Endo S, Sakai F, Yoshimura I. A new whole-mouth gustatory test procedure. 1. Thresholds and principal components analysis in healthy men and women. Acta Otolaryngol Suppl 2002a;(546):39-48. PMID 12132620
219: Yamauchi Y, Endo S, Yoshimura I. A new whole-mouth gustatory test procedure. II. Effects of aging, gender and smoking. Acta Otolaryngol Suppl 2002b;(546):49-59. PMID 12132621
220: Yao Q, Doyle ME, Liu QR, et al. Long-term dysfunction of taste papillae in SARS-CoV-2. NEJM Evid 2023;2(9):10.1056/evidoa2300046. PMID 38145006
221: Yusuf T, Raji YR, Lasisi TJ, et al. Predictors of taste dysfunction and its severity among patients with chronic kidney disease. Ear Nose Throat J 2023;102(12):787-93. PMID 34281407
222: Zakrzewska J, Buchanan JA. Burning mouth syndrome. BMJ Clin Evid 2016;2016:1301. PMID 26745781
223: References especially recommended by the author or editor for general reading.

Patient Profile

Age range of presentation: 0 to 65+ years
Sex preponderance: No sex preponderance
Population groups selectively affected: No population group selective affected
Occupation groups selectively affected: No occupation group selectively affected

ICD & OMIM codes

ICD-10: Unspecified disturbances of smell and taste: R43.9

Other disturbances of smell and taste: R43.8

Disturbances of smell and taste: R43

Parageusia: R43.2

Post COVID-19 condition, loss of taste: R43.8
ICD-11: Disturbances of smell and taste: MB41

Other specified disturbances of smell and taste: MB41.Y

Disturbances of smell and taste, unspecified: MB41.Z

Dysgeusia: MB41.2

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Disorders of gustation

Associated Disorders

COVID-19
SARS-CoV-2
Temporal lobe epilepsy
Oral psoriasis
Migraine
- Schizophrenia
- Schizoaffective
- Bipolar
- Burning mouth syndrome
- Stroke
- Cerebrovascular disease
- Synucleinopathy
- Presbygeusia

Differential Diagnosis

impairment of olfaction
adverse drug reaction
upper respiratory infection
viral illness
facial nerve disorder
- glossopharyngeal nerve disorder
- brainstem lesion
- opercular lesion

Also Relevant

Chemotherapy: neurologic complications
Disorders of olfaction
Drug-induced disturbances of smell and taste
Hyposmia in neurodegenerative disorders
Traumatic cranial neuropathy

Clinical Categories

General Neurology

Disorders of gustation

Disorders of gustation

Introduction

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Terminology for Gustatory Function

Gustatory hallucinations (phantageusias)

Table 2. Frequency of Hallucinations by Modality in Patients with Psychotic Disorders

Prognosis and complications

Biological basis

Etiology and pathogenesis

Gustatory anatomy

Table 3. Comparison of Ictal and Release Visual Hallucinations

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Media

References

Contributors

Author

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Nystagmus

Third nerve palsy

Brain death/death by neurologic criteria

Outpatient rehabilitation of chronic neurologic conditions

Disorders of gustation

Introduction

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Terminology for Gustatory Function

Gustatory hallucinations (phantageusias)

Table 2. Frequency of Hallucinations by Modality in Patients with Psychotic Disorders

Prognosis and complications

Biological basis

Etiology and pathogenesis

Gustatory anatomy

Table 3. Comparison of Ictal and Release Visual Hallucinations

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Media

References

Contributors

Author

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Nystagmus

Third nerve palsy

Brain death/death by neurologic criteria

Outpatient rehabilitation of chronic neurologic conditions

This is an article preview.
Start a Free Account
to access the full version.